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Astrocytes might play an important role in demyelinating diseases such as multiple 
sclerosis (MS) since serum autoantibodies directed against the astrocytic water channel 
aquaporin-4 cause inflammatory demyelinating lesions in the MS-related disease 
neuromyelitis optica. Oral cuprizone challenge leads to demyelination of the corpus 
callosum and cortex in mice, whereby the blood-brain-barrier remains intact. Astrocytic 
activation of nuclear factor kappa of activated B cells (NF-κB) plays a key role for mediating 
demyelination under cuprizone. Recent clinical trials in MS indicate that laquinimod (LAQ) is 
an oral substance with more pronounced effects on disability and brain atrophy than on 
relapses suggesting that LAQ might exert effects not only on peripheral immune cells, but 
also on central nervous system (CNS)-resident cells. 
The aim of the present study was to investigate intrinsic and therapy-induced 
astrocytic effects on cuprizone-induced pathology in mice. One aim was to assess the effects 
of LAQ on toxic demyelination. A further aim was to study the impact of increased astrocytic 
glial fibrillary acidic protein (GFAP) expression on cuprizone-induced changes.  
Eight- to ten-weeks-old male C57BL/6 mice were given 0.25% cuprizone for one or six 
weeks. Histological and immunohistochemical analyses were performed to evaluate therapy-
induced and astrocytic effects on cuprizone-induced changes on glia, myelin and axons in the 
corpus callosum. In addition, astrocytic NF-κB activation was assessed by nuclear 
translocation of p65 in GFAP-positive astrocytes. 
To examine the effects of LAQ, mice were treated with 0, 5 or 25 mg/kg LAQ per day 
during cuprizone challenge. After one week of cuprizone, oligodendrocyte apoptosis was 
reduced by 62% in mice treated with 25 mg/kg LAQ compared to vehicle-treated animals. 
After six weeks of cuprizone, LAQ reduced demyelination in a dose-dependent manner and 
attenuated microglial activation, axonal damage and reactive astrogliosis compared to the 
vehicle group. Similar results were observed in recombination activating gene 1 (Rag1)-
deficient mice constitutively lacking T and B cells indicating that the effect of LAQ in the 
cuprizone model is CNS-intrinsic. Astrocytic NF-κB activation was significantly decreased by 
46% under 25 mg/kg LAQ compared to the vehicle group after six weeks of cuprizone. These 
data indicate that LAQ might protect from cuprizone-induced pathology through CNS-
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intrinsic mechanisms by reducing NF-κB activation in astrocytes. Recently published data in 
primary astrocytic cultures support these findings by showing that LAQ directly inhibited the 
astrocytic NF-κB activation and thereby down-regulated the astrocytic pro-inflammatory 
response. 
The impact of increased astrogliosis on cuprizone-induced demyelination was 
evaluated in transgenic mice overexpressing human GFAP. These animals show an increased 
astrogliosis even without external stimuli. After one week of cuprizone, transgenic mice 
displayed still higher densities of preserved mature oligodendrocytes and an 80% reduction 
of oligodendroglial apoptoses compared to the corresponding wild type animals. After six 
weeks of cuprizone, transgenic mice showed decreased demyelination, microglial activation 
and axonal damage as well as an 80% reduction of astrocytic NF-κB activation compared to 
wild type animals. These data indicate that reduced astrocytic NF-κB activation might also 
contribute to reduced cuprizone-induced pathology in mice overexpressing human GFAP.  
These data suggest that down-regulating the astrocytic NF-κB activation might be a 
potential therapeutic approach for the future treatment of demyelinating diseases such as 
MS. The CNS-intrinsic effects of LAQ on astrocytic activation might explain the clinical 
findings of more pronounced effects on disability and brain atrophy than on relapses.        
The findings from this work could contribute to a better understanding and further 
development of novel protective therapies limiting tissue damage in demyelinating diseases 
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1.1 Multiple sclerosis 
Multiple sclerosis (MS), also known as encephalomyelitis disseminata, is the most 
common chronic neurological disease leading to disability in early to middle adulthood. 
MS was first described by Jean Martin Charcot in 1868 and is currently believed to be an 
autoimmune disorder causing inflammatory demyelination in the central nervous system 
(CNS) including the brain and spinal cord. Traditionally, demyelinated areas were thought to 
be predominantly located in the white matter and lesions in the white matter were regarded 
as most important pathological feature in MS. However, recent studies have demonstrated 
extensive grey matter demyelination as well as wide-spread changes in the normal-
appearing white matter (NAWM). Diffuse pathological changes in the NAWM as well as 
white and grey matter atrophy indicate that changes in MS are not restricted to focal lesions, 
but affect the whole CNS. These diffuse changes are not well understood, but axonal and 
glial changes are likely to play a role. 
 
1.1.1 Clinical course and diagnostics 
The disease course of MS differs from patient to patient and is not exactly 
predictable. Symptoms occur either as discrete attacks (relapsing forms) or slowly 
accumulating over time (progressive forms). At disease onset two main courses of the 
disease exist: The first and most common form is the relapsing-remitting form of MS (RR-
MS) which affects about 80% to 85% of patients. Early symptoms usually include visual as 
well as sensory disturbances, limb weakness, clumsiness and gait ataxia. RR-MS patients 
typically develop suddenly occurring symptoms evolving over several days and improving 
within weeks. After a relapse, remaining signs of CNS dysfunction may persist. 
Later on during the disease course, most of the cases (about 80% of RR-MS patients 
in 20 years) show a continuous disease progression which is not related to relapses 
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(secondary progressive (SP)-MS) (Lublin and Reingold, 1996; Kremenchutzky et al., 2006). 
Patients with SP-MS accumulate progressive disability over time. 
About 15% to 20% of patients suffer from the second form of MS showing a gradually 
progressive clinical course from onset with no acute attacks known as primary progressive 
(PP)-MS. Typical symptoms include leg weakness, as well as bowel and bladder symptoms. 
Up to now, the factors which are responsible for the different courses of the disease are not 
known.  
As initial stage of the clinical disease, the clinically isolated syndrome (CIS) is 
described as first neurologic episode that lasts at least 24 hours and is caused by 
inflammatory demyelination of the CNS. An episode may be monofocal in which symptoms 
are caused by a single lesion in the CNS or multifocal in which multiple sites exhibit 
symptoms. Not all patients who experience a CIS go on to develop MS. However, if CIS 
patients show oligoclonal bands within the cerebrospinal fluid (CSF) and disseminated brain 
lesions on magnetic resonance imaging (MRI), then these patients have a high risk of 
developing MS with further relapses (Morrissey et al., 1993).  
MS is typically diagnosed based on the clinical presentation as well as evidence of 
oligoclonal immunoglobulin G (IgG) bands in CSF and disseminated lesions on MRI (Miller et 
al., 1989). The so-called “McDonald criteria” are diagnostic criteria for MS focusing on 
clinical and radiologic data of the dissemination of MS lesions in time and space. Using the 
McDonald criteria the outcome of a diagnostic evaluation is “MS”, “possible MS” or “not 
MS” (McDonald et al., 2001). A recently revision of the McDonald criteria allows a more 
rapid diagnosis of MS by a single MRI scan (Polman et al., 2011). Thus, a rapid diagnosis can 
be made by a single brain MRI study presenting lesion dissemination in time and space and 
both active lesions uptaking gadolinium as well as non-enhancing lesions. Lesion 
dissemination in space is presented by more than one T2 lesion in at least two of four areas 
of the CNS: Periventricular, juxtacortical, infratentorial and spinal cord. Lesion dissemination 
in time is presented either by an asymptomatic gadolinium-enhancing lesion on the first scan 
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1.1.2 Established treatment 
During the acute phases of MS, the standard treatment consists of high-dose 
methylprednisolone, a synthethic glucocorticoid, given intravenously (i. v.) for three to five 
days. If the treatment with methylprednisolone fails to improve symptoms within two 
weeks, plasmapheresis will be considered in patients with severe symptoms. Different 
immunomodulatory drugs are available for long-term treatment of RR-MS: Glatiramer 
acetate (Copaxone), Interferon beta (IFNβ) 1a (Avonex), IFNβ 1a (Rebif) and IFNβ 1b 
(Betaferon). Copaxone is administered subcutaneously (s. c.) and is supposed to 
attenuate pro-inflammatory T cell responses showing T helper cell 2 (Th2) activation (Vieira 
et al., 2003). IFNβ proteins have antiviral as well as immunomodulatory properties. 
Two forms of recombinant IFNβ proteins are available for MS therapy - IFNβ 1a and 1b. 
IFNβ 1a is produced by mammalian cells whereas IFNβ 1b is produced in genetically 
modified E. coli. Avonex is administered intramuscular (i. m.), Rebif and Betaferon by  
s. c. application. 
If patients continue to have relapses under the standard immunomodulatory 
treatments, then an escalation therapy should be considered. The first choice treatments are 
natalizumab (Tysabri) applied i. v. and fingolimod (Gilenya) given orally. Both drugs are 
more potent and have immunomodulatory properties. Tysabri is a recombinant 
monoclonal antibody produced in murine myeloma cells. Natalizumab appears to diminish 
the transmission of immune cells into the CNS by binding to α4β1-integrin receptor 
molecules on the surfaces of lymphocytes expressing α4-integrin expressed by T 
lymphocytes. Tysabri blocks immune cell adhesion to blood vessel walls and hence blocks 
migration of T cells into the CNS (Miller et al., 2003; Rice et al., 2005). Fingolimod is a 
sphingosine 1-phosphate receptor modulator that inhibits migration of lymphocytes out of 
lymph nodes into the circulation. Hence, Gilenya prevents lymphocytes to reach the CNS 
and as a consequence reduces relapses and progression of the disease (Chiba et al., 1998). 
The second choice for intensified treatment of RR-MS is mitoxantrone.  
All these drugs mainly target the peripheral immune system. Medications with 
myelin- or axon-protecting effects could prevent the increase in disability through the course 
of MS by limiting the tissue damage, especially neurodegeneration. Hence, there is a need 
for medications entering the CNS and directly inhibit myelin and axonal damage. Since most 
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of the established drugs need parenteral application, the development of oral medications 
was necessary and facilitates the daily life for patients with fear or weariness of injections. 
 
1.2 Pathogenesis and pathology of MS 
1.2.1 Epidemiology and Etiology  
The prevalence of MS is approximately 2500,000 patients worldwide and varies 
around the world. A north to south gradient in disease prevalence shows high prevalence 
rates on the northern hemisphere compared to low rates on the southern (Kurtzke et al., 
1979). The prevalence is highest in northern Europe, southern Australia and the middle part 
of North America. In Germany about 127 people are affected per 100,000 persons (Hein and 
Hopfenmüller, 2000). Approximately 120,000 cases were reported in 2001 in Germany, 
whereby 2,500 patients are newly diagnosed every year. Migration studies show that 
migration from an area of high prevalence of MS to an area of low prevalence before the age 
of 15 to 16 leads to an acquisition of the low risk, whereas migration after an age of 15 to 16 
does not change the risk (Kurtzke et al., 1970; Kurtzke, 2000).  
Females are affected more often than males suggesting that sex hormones are one 
factor influencing MS. MS has a female predominance which has developed from 2:1 to 3:1. 
Recent studies indicate that an increase in the number of female RR-MS patients leads to a 
renewed increase in sex ratio of MS (Ramagopalan et al., 2010). The relevance of sex 
hormons is supported by lower relapse rates during pregnancy and disease rebound after 
pregnancy (Runmarker et al., 1995). Further evidence comes from studies reporting a 
worsening of MS during menstruation and the ameliorating therapeutic effects of the 
pregnancy hormone estriol in RR-MS (Sicotte et al., 2002).  
Genetic and environmental factors influence the development of MS. Family and twin 
studies indicate that the prevalence is substantially increased in family members of MS 
patients. First-degree relatives of a MS patient (such as children, siblings or non-identical 
twins) have a 2.5% to 5% risk of developing the disease. The risk of MS for second-degree 
relatives (such as cousins, uncles/aunts, nephew/nieces) is around 1%. For an identical twin 
of a MS patient who shares all the same genes is the risk of MS increased to 25% to 30% 
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(Ebers et al., 1986; Sadovnick et al., 1993). After searching for individual susceptibility genes, 
the most striking gene or genes are found on chromosome 6p21 in the area of the major 
histocompatibility complex (histocompatibility leukocyte antigen (HLA) in humans). The risk 
for MS is increased with the presence of one or more HLA-DRB1*15 alleles (Banwell et al., 
2011). This allele is considered to play a role in 17% to 60% of the hereditary MS cases 
(Haines et al., 1998). Recent genetic studies investigating over 7,000 MS patients identified 
over 50 genetic factors involving mainly immunologically relevant genes, but also 
environmental factors such as vitamin D (Sawcer et al., 2011). However, a contribution of 
non-genetic factors to MS etiology is also clear since identical twins show a concordance rate 
of only 25% to 30% (Ebers et al., 1986; Sadovnick et al., 1993).  
Discussed environmental factors are sunlight exposure, vitamin D, hygiene, smoking 
and geographical microbiological factors. One possible factor could be the decrease in 
sunlight exposure depending on the latitude leading to a decrease in UV radiation and 
decreased biosynthesis of vitamin D (Acheson et al., 1960). A further factor for MS 
represents the hygiene status since it comes to a delayed or overall reduction in childhood 
infections in developed countries leading to an increase in autoimmune reactions/diseases 
(Th1-mediated) and allergies (Th2-mediated) (Strachan, 1989; Folkerts et al., 2000). Hence, 
the hygiene hypothesis suggests that there is a shift from Th1 to Th2 responses as a result of 
the cleaner environment (Strachan, 1989; Folkerts et al., 2000).  
As additional environmental factor, infectious agents have been postulated to be 
potential triggers of MS. Many viruses have been discussed, but especially Epstein-Barr virus 
(EBV) seems to be related to MS. An association between EBV and pediatric MS is found 
since serological evidence for remote EBV is present in ca. 80% of pediatric MS patients 
(Alotaibi et al., 2004), but only in 42% of healthy control cases. It is thought that EBV shows 
similarities to myelin basic protein (MBP) and hence molecular mimicry involving HLA 
molecules has been debated (Lang et al., 2002). Furthermore, the interaction of EBV and 
HLA-DRB1*15 is discussed since HLA alleles recognize EBV nuclear antigen 1 (EBNA-1) 
epitopes. 
Exposure to cigarette smoke is also discussed as further environmental risk factor for 
MS. Smokers have an approximately 1.5 higher risk for developing MS than non-smokers and 
they show more rapid disease advancement (Riise et al., 2003).  
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1.2.2 Pathogenesis of MS 
Based on data from animal experiments, MS is generally considered as a 
predominantly T cell-mediated autoimmune disease. Findings from animals with 
experimental autoimmune encephalomyelitis (EAE) suggest that MS develops after 
activation of autoreactive T lymphocytes (CD4+ and CD8+) leading to inflammatory 
demyelination of the CNS (Schluesener and Wekerle, 1985; Sedgwick and Mason, 1986; 
Huseby et al., 2001). Activated T cells are thought to cross the blood-brain-barrier (BBB) and 
enter the CNS (Hickey et al., 1991). Once in the CNS, these T cells further compromise the 
integrity of the BBB and are thought to target one or more myelin antigens within the CNS 
(Westland et al., 1999). B cells are also thought to play a role in the pathogenesis of MS. 
T cells from MS patients do not differ quantitatively, but qualitatively in comparison to 
healthy subjects. Myelin-reactive T and B cells from MS patients show a memory or activated 
phenotype and can activate CD4+ T cells, whereas healthy persons typically display a naive 
phenotype (Lovett-Racke et al., 1998; Scholz et al., 1998).  
Autoreactive T cells cause inflammation within the CNS by secretion of 
proinflammatory cytokines: Activation of CD4+ autoreactive T cells results in secretion of the 
proinflammatory cytokines interleukin (IL)-2, IFNγ and tumor necrosis factor alpha (TNFα) 
and hence leading to an injurious cytokine phenotype (CD4+ Th1). In contrast, myelin-
reactive T cells from healthy persons produce more cytokines leading to an anti-
inflammatory cytokine phenotype (CD4+ Th2) (Hermans et al., 1997). Human T cells can 
differentiate into Th1 lymphocytes after activation of the transcription factor signal 
transducer and activator of transcription (Stat)-4 in these lymphocytes by cytokines (such as 
IL-12) or type 1 interferons (such as IFNγ) (Bacon et al., 1995). IL-4 and IL-10 are involved in 
the differentiation of CD4+ T lymphocytes favoring Th2 outcomes in EAE (Betelli et al., 1998; 
Falcone et al., 1998). Besides Th1 and Th2 cells, the role of Th17 proinflammatory T cells in 
MS is also discussed since Th17 cells have a central role in disease development which is 
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1.2.3 Pathology of MS  
MS is characterized by multifocal plaques. MS lesions can occur anywhere in the CNS, 
but most lesions arise in the optic nerve, periventricular areas, brain stem and spinal cord. 
As the most important pathological feature, MS lesions in the white matter have been 
considered. Macroscopically, lesions are brownish-grey with harder consistency because of 
gliotic processes (Charcot, 1868; 1873). Microscopically, MS has four pathological hallmarks: 
Inflammation, demyelination, axonal damage and astrogliosis. Acute lesions display 
pronounced inflammation dominated by T cells and macrophages, followed by B cells and 
plasma cells (Lucchinetti et al., 2000; Frischer et al., 2009).  
Demyelination is associated with axonal damage and reactive astrogliosis in the CNS. 
Axonal injury starts early in the disease course (Ferguson et al., 1997; Trapp et al., 1998; 
Kuhlmann et al., 2002). This acute axonal damage seems to play an important role because it 
leads to irreversible axonal loss that is thought to be responsible for chronic disability 
(Bjartmar and Trapp, 2001). As response to tissue damage, astrocytes underlying cellular and 
functional changes known as reactive astrogliosis including elevation of glial fibrillary acidic 
protein (GFAP) (Roessmann and Gambetti, 1986). 
MS lesions are distinguished according to their stage of demyelinating activity and 
the presence of immune cells (Brück et al., 1995). Active demyelinating lesions are 
characterized by macrophages engulfing myelin debris and are distributed throughout the 
lesion or at the lesion edge. In contrast, macrophages engulfing myelin debris are only 
located at the rim of the lesion in smouldering lesions (Prineas et al., 2001). In chronic 
inactive lesions only single T cells are present in perivascular regions without evidence for 
ongoing demyelination. 
Early, actively MS lesions are considered as heterogeneous (Lucchinetti et al., 2000). 
The concept of heterogeneity is based on four different patterns of demyelination 
categorised according to their myelin protein loss, geography and extension of plaques, 
pattern of oligodendrocyte destruction and the immunopathological evidence of 
complement activation. Pattern I and II are similar to T-cell-mediated or T-cell plus antibody-
mediated autoimmune encephalomyelitis. However, the other two patterns, pattern III and 
IV, are based on oligodendrocyte dystrophy which is similar to either toxin- or virus-induced 
demyelination rather than autoimmunity.  
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In MS patients, grey matter is known to undergo extensive changes especially in 
chronic MS patients. More than 90% of patients with chronic MS show cortical lesions 
(Wegner et al., 2006). Grey matter lesions are present in areas of cortical, deep and spinal 
grey matter (Wegner and Stadelmann, 2009). Three types of cortical lesions have been 
described in MS: Leukocortical lesions (type I), intracortical (type II) and subpial lesions (type 
III). Type I lesions involve grey and immediately adjacent white matter. Type II lesions lie 
purely within the neocortex and type III lesions extend from the pial surface into the cortex. 
Subpial lesions (type III) are the most extensive and can cover up to 70% of the cortical area 
in MS patients (Bø et al., 2003). 
Diffuse pathological changes in NAWM and cortical demyelination are mainly found 
in progressive MS, but even patients with early MS show cortical demyelination (Lucchinetti 
et al., 2011). The NAWM outside of plaques shows inflammatory processes and a 
generalized activation of microglia (Kutzelnigg et al., 2005). Furthermore, demyelination and 
axonal damage in focal lesions of MS patients extend into NAWM and lead to reduced 
original lesion site (Evangelou et al., 2000a). Axonal damage in plaques followed by 
secondary Wallerian degeneration has been discussed to result from diffuse changes of the 
NAWM (Evangelou et al., 2000b; Lovas et al., 2000). Additionally, an increased BBB 
permeability is observed in NAWM (Kirk et al., 2003). 
After pathological loss of myelin, remyelination may occur. During this process new 
myelin sheaths are generated around axons. Initially, oligodendrocyte precursor cells (OPC) 
are recruited to the lesion and then differentiate into myelinating oligodendrocytes which 
enwrap the demyelinated axons with new myelin sheaths (Levine and Reynolds, 1999). 
However, in the majority of MS patients, remyelination is impaired even if OPC are present 
(Chang et al., 2002). MRI studies from autopsies of MS patients demonstrate that only 40% 
of lesions show remyelinated areas (Barkhof et al., 2003). Recent studies show that 
remyelination is more frequent in early MS lesions (ca. 80% remyelinated) compared to 
chronic MS lesions (ca. 60% remyelinated) (Goldschmidt et al., 2009). One explanation for 
the limited remyelination in the majority of chronic MS lesions might be an impaired 
differentiation of OPC into myelinating oligodendrocytes (Kuhlmann et al., 2008). 
Experimental data indicate that the remyelination capacity decreases with age in 
mice after cuprizone-induced demyelination, whereby a restricted oligodendrocyte 
differentiation is thought to play a role (Shen et al., 2008). Other possible explanations for an 
                                                                                                                                                             1 Introduction 
9 
 
impaired remyelination come from experiments in mice with lysolecithin-induced 
demyelination. In this animal model, the depletion of macrophages leads to a delayed OPC 
recruitment and hence impaired remyelination (Kotter et al., 2005). Further studies in 
recombination activation gene (Rag) 1-deficient mice lacking constitutively T and B cells  
demonstrate an inhibition of remyelination processes after lysolecithin-induced 
demyelination (Bieber et al., 2003). 
 
1.3 Animal models of MS 
1.3.1 Experimental autoimmune encephalomyelitis  
Experimental autoimmune encephalomyelitis (EAE) represents the most common 
animal model of MS. This autoimmune disease causes inflammatory demyelinating lesions 
within the CNS and is most frequently used in rats and mice. Depending on species, EAE 
pathology differs. In mice, white matter of the spinal cord is mainly affected.  
EAE can be induced by active immunization with myelin antigens such as MBP, myelin 
oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP) or myelin-associated 
oligodendrocytic basic protein and 2`,3`-cyclic nucleotide 3`-phosphodiesterase (CNP). EAE is 
commonly induced by active immunization of mice with a small peptide carrying the 
sequence of MOG from amino acid position 35 to 55 (MOG35-55) which is emulsified in 
complete Freund`s adjuvant. EAE can also be induced by passive adoptive transfer of 
encephalitogenic T cells from actively immunized animals into naïve mice.  
The EAE model is often used to investigate potential new treatments for MS. Previous 
studies show an inhibition of disease in EAE after treatment with IFNβ (Yasuda et al., 1999) 
and copolymer-1 (Teitelbaum et al., 1996). The oral immunomodulator linomide 
(Roquinimex) was also tested in this model and shown to inhibit EAE (Karussis et al., 
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1.3.2 Cuprizone-induced demyelination 
Cuprizone has already been established as a neurotoxin for different species in the 
1960s (Carlton, 1967). Historically, feeding of high cuprizone concentrations was used to 
cause scrapie-like spongiform encephalopathy in different species such as rats, mice, guinea 
pigs and hamsters (Carlton, 1967, 1969). These high concentrations such as 0.5% cuprizone 
are highly toxic when administered early during development and produce giant hepatic 
mitochondria in mice (Suzuki, 1969; Kesterson and Carlton, 1972; Flatmark et al., 1980). 
The main pathological features of mice treated with high cuprizone concentrations are brain 
edema, demyelination, astrogliosis and hydrocephalus (Pattison and Jebbett, 1971a; b). 
Feeding the neurotoxicant cuprizone at a dose of 0.2% to 0.25% to eight to ten-
weeks-old C57BL/6 mice leads to consistent demyelination of the corpus callosum and 
cortex after five to six weeks (Hiremath et al., 1998; Skripuletz et al., 2008). Cuprizone is 
known to induce oligodendrocyte apoptosis starting already after two days of cuprizone 
feeding and reaching maximal numbers after 10 and 21 days (Hesse et al., 2010; Buschmann 
et al., 2012). The loss of oligodendrocytes results in subsequent microglial activation, 
astrogliosis and demyelination in the following four to five weeks (Hiremath et al., 1998). 
The BBB is intact in this model and cuprizone-induced demyelination is thought to be 
mediated by direct CNS effects which take place in the near absence of immune cells since 
Rag1-deficient mice lacking constitutively T and B cells are indistinguishable from wild type 
mice after cuprizone feeding (Matsushima and Morell, 2001; Hiremath et al., 2008).           
The extent of demyelination differs regionally and temporally in species as well as in species 
strain (Skripuletz et al., 2008; Taylor et al., 2009).  
One week after removal of the toxin spontaneous and complete remyelination occurs 
in young mice (Blakemore, 1973). Therefore, the murine cuprizone-induced de- and 
remyelination model is a widely used non-invasive model to investigate effects directly 
related to demyelination and remyelination within the CNS.  
The exact mechanism of cuprizone-induced oligodendrocyte death is not well 
understood, but it is assumed that the copper chelator cuprizone leads to copper deficiency. 
However, administration of copper at high levels up to 100 ppn does not reduce cuprizone-
induced effects suggesting that copper deficiency cannot be the major mechanism of 
cuprizone action (Carlton, 1967). It has been speculated whether a disturbed energy 
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metabolism might lead to oligodendrocyte death (Kipp et al., 2009). Mitochondria are 
responsible for the energy metabolism by producing adenosine-5-triphosphate (ATP) and 
they are important for calcium homeostasis and apoptosis. Copper-containing mitochondrial 
enzymes such as monoamine oxidase, cytochrome oxidase and superoxide dismutase might 
cause a disturbance of energy metabolism due to copper chelating. 
Previous studies indicate a crucial role of astrocytic NF-κB activation for cuprizone-
induced oligodendrocyte damage (Raasch et al., 2011). In this study, inhibition of NF-κB 
activation in IκB kinase-deficient mice caused a preservation of cerebral myelin under 
cuprizone as well as reduced expression of pro-inflammatory mediators and decreased glial 
response. Only mice deficient in astrocytic, but not oligodendroglial, NF-κB activation 
showed myelin preservation under cuprizone. Further support for an astrocytic contribution 
in this model comes from studies with mice constitutively deficient in the astrocytic adaptor 
protein Act1 (NF-κB activator 1). These mice also show reduced cuprizone-induced 
demyelination (Kang et al., 2012). Cuprizone-induced demyelination is also reduced in mice 
constitutively deficient in IL-17A and IL-17 receptor (Kang et al., 2012). Neuropathological 
studies demonstrate that IL-17 is also expressed in astrocytes in MS lesions (Tzartos et al., 
2008).  
Data on in vitro effects of cuprizone are controversial. Previous studies reported an 
inhibition of oligodendrocyte maturation without diminishing the numbers of precursors 
(Cammer, 1999). However, other studies indicated no direct effect of cuprizone on 
oligodendrocytes alone. Only the combination of cuprizone together with TNFα and/or IFNγ 
increased cell death (Pasquini et al., 2007). A third study reported neither astrocytic nor 
microglial NF-κB activation in vitro after cuprizone treatment, either alone or in combination 
with lipopolysaccharide (LPS) or TNFα (Raasch et al., 2011). 
 
1.3.3 Focal lysolecithin-induced demyelination 
Lysolecithin (L-α-lysophosphatidyl choline; LPC) is a membrane solubilizing agent and 
has been used to induce focal areas of demyelination (Hall, 1972) in mice, rats, rabbits and 
cats. Stereotactic injection of LPC into the spinal white matter of rodents produces ellipsoid-
shaped areas of demyelination (Woodruff and Franklin, 1999a; Blakemore and Franklin, 
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2008). So far, only few studies are published focusing on LPC-induced lesions in the corpus 
callosum of mice.  
Focal injection of LPC leads at least partially to focal BBB leakage followed by 
infiltration of peripheral inflammatory cells. T cells, neutrophils and monocytes are seen at 
the injection site after 6-12 hours following LPC injection. At later time points, macrophages 
and microglia are recruited to the injection site and become activated (Ousman and David, 
2000). Spontaneous remyelination starts a few days after LPC injection. In mice, 
remyelination takes place within three weeks after LPC injection, when most of the 
demyelinated axons are enwrapped by myelinating cells (Blakemore, 1976; Jeffery and 
Blakemore, 1995).  
LPC is particularly toxic for myelin and partially spares oligodendrocytes (Blakemore 
and Franklin, 2008). Other studies claim direct toxic effects of LPC on myelin-producing cells 
(Woodruff and Franklin, 1999b). In addition, axons and astrocytes can also be affected 
around the injection site.  
 
1.4 Treatment of inflammatory demyelinating diseases with the 
new drug laquinimod 
1.4.1 Laquinimod in MS 
Initially, Roquinimex - the predecessor of laquinimod (LAQ) - demonstrated clinical 
efficacy in a phase II study showing significantly reduced MRI and clinical activity (Wolinsky 
et al., 2000). However, phase III studies revealed cardiopulmonary toxicities of Roquinimex 
leading to termination of development of the drug (Noseworthy et al., 2000). Finally, LAQ 
was then produced by structural modifications that optimized efficacy and minimized 
toxicity (Jönsson et al., 2004). In detail, the 5-H and 12-N-methyl groups on the 
Roquinimex molecule were substituted by 5-Cl and 12-N-ethyl groups (Fig. 1).  
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Fig. 1: Structural formula of Roquinimex and laquinimod. The 5-H and 12-N-methyl groups on the 
Roquinimex molecule are substituted by 5-Cl and 12-N-ethyl groups on the laquinimod molecule. 
 
 
LAQ is an oral immunomodulatory substance that has been shown to be effective, 
safe and well-tolerated. Initial phase II studies indicated that LAQ reduced the formation of 
MRI-active lesions in RR-MS (Polman et al., 2005; Comi et al., 2008). Recent findings from 
the first phase III study “ALLEGRO” show that LAQ has even more pronounced effects on 
sustained disability progression as well as on brain atrophy compared to its effect on 
relapses (Comi et al., 2012). In this phase III study, LAQ led to a significant reduction of the 
risk for sustained disability progression and of the rate of MRI-measured brain volume loss 
by about one-third. In the second phase III study “BRAVO”, adjusted to baseline expanded 
disability status scale and disease activity, LAQ reduced the annualised relapse rate by 21%, 
the risk of disability progression by 30% and brain volume loss by about 28%. 
More evidence for a neuroprotective effect of LAQ comes from a recent study in 
which LAQ-treated MS patients show higher serum levels of brain-derived neurotrophic 
factor (BDNF) (Thöne et al., 2012). Together with the clinical effects from the phase III 
studies “ALLEGRO” and “BRAVO”, these data suggest that LAQ might have direct CNS-
protective effects in addition to its known peripheral anti-inflammatory properties. Analyses 
of transcriptional gene-expression profiles induced by LAQ in vitro in peripheral blood 
mononuclear cells (PBMC) derived from healthy subjects and RR-MS patients indicate that 
LAQ suppresses the NF-κB pathway (Gurevich et al., 2010). 
Up to now, the observed discrepancy between more pronounced effects of LAQ on 
disability and brain atrophy than on relapses is not completely understood. An attractive 
hypothesis is that LAQ might exert effects not only on peripheral cells, but also on CNS-
resident cells. 
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1.4.2 Laquinimod in EAE 
As principle autoimmune animal model of MS, the EAE has proven useful in the 
development of new treatments such as LAQ for MS. Previous studies indicate that LAQ 
inhibits relapses in EAE when given before disease onset in mice (Brunmark et al., 2002) and 
Lewis rats (Yang et al., 2004) and when given after disease onset in C57BL/6 mice (Runstrom 
et al., 2006). Previous studies using whole-body autoradiography demonstrate that 7% to 8% 
of LAQ penetrates through the intact BBB of naive mice and reaches the brain in relation to 
the blood concentration. In contrast, in EAE mice 13% to 14% of LAQ reaches the brain, since 
the BBB permeability is increased (Brück and Wegner, 2011). The analyses of cytokine 
profiles indicate that LAQ redirects the cytokine production in favour of the Th2/Th3 
cytokines IL-4, IL-10 and transforming growth factor beta (TGFβ) (Yang et al., 2004).  
In immunized C57BL/6 mice, clinical signs of EAE are reduced in a dose-dependent 
manner after preventive LAQ treatment at a dose of 5 mg/kg or 25 mg/kg (Wegner et al., 
2010). Therapeutic LAQ treatment at a dose of 25 mg/kg also reduces already present 
clinical signs of EAE. Furthermore, preventive and therapeutic LAQ treatment regimens lead 
to a reduction of clinical signs, inflammation and demyelination, which might be mediated 
by down-regulation of proinflammatory cytokines such as IL-17 by LAQ. Within EAE lesions, 
less acute axonal damage is observed in LAQ-treated animals compared to vehicle-treated 
mice (Wegner et al., 2010).  
Recent studies indicate that LAQ induces type II myeloid cells and increases 
regulatory T cells (Schulze-Topphoff et al., 2012). The authors of this study suggest that LAQ 
modulates adaptive T cell immune responses by affecting cells of the innate immune system 
and hence may not influence T cells directly. Further studies demonstrate a more severe EAE 
disease course in BDNF conditional knockout mice lacking BDNF expression in myeloid cells 
as well as in T cells. These findings indicate that LAQ might act via modulation of BDNF 
(Thöne et al., 2012). Other studies show that LAQ treatment leads to retention of 
proinflammatory monocytes in the blood, whereby LAQ reduces their entry into the CNS and 
prevents EAE (Mishra et al., 2012).  
These experimental data mainly confirm that LAQ has peripheral immune effects and 
also shows potential central effects on BDNF expression, but these data do not fully explain 
the neuroprotective effects observed in the phase III clinical trials “ALLEGRO” and “BRAVO”. 
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Up to now, there are no studies in non-inflammatory animal models to test whether LAQ 
directly affects CNS-resident cells. 
 
1.5 Role of astrocytic factors in inflammatory demyelinating 
diseases 
Astrocytes are thought to play an active and dual role in CNS inflammatory diseases 
such as MS. On the one hand, astrocytes can enhance the immune response and inhibit 
myelin repair. On the other hand they can be protective and limit CNS inflammation and 
support oligodendrocyte and axonal regeneration (Sofroniew, 2009).  
As supportive glial cell component in neural tissue, astrocytes express GFAP which is 
a type Ill intermediate filament protein. A marked increase of GFAP is a major feature of 
complex changes occurring in astrocytes after demyelination and most other CNS injuries. 
GFAP is mainly expressed in astrocytes of the CNS, but also in multipotent radial neural stem 
cells of the brain and in astrocyte-related cells outside the CNS (Sofroniew and Vinters, 
2010).  
 
1.5.1 Astrocytic changes in MS 
Astrocytes can prevent widespread tissue damage by formation of a glial scar around 
demyelinated lesions which serves as a physical barrier. However, hyaluron which is 
produced by reactive astrocytes accumulates in chronic demyelinated MS lesions and 
inhibits OPC maturation (Back et al., 2005). Although it is not fully understood which role 
astrocytes play in MS, some studies strengthen that astrocytes might be important for MS. 
Previous studies show that reactive astrocytes in active and chronic MS lesions up-regulate 
the voltage-sensitive sodium channel Nav1.5 (Black et al., 2010). Furthermore, GFAP is 
increased in CSF in patients with progressive MS (Malmeström et al., 2003) and astrocytic   
IL-17 expression is found in active areas of MS lesions (Tzartos et al., 2008). Additionally, 
serum levels of antibodies to the astrocytic inwardly rectifying potassium channel (KIR) 4.1 
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are elevated in MS patients compared to healthy persons or those with other neurological 
diseases (Srivastava et al., 2012). 
Further evidence for an important role of astrocytes in demyelinating diseases comes 
from the related disease neuromyelitis optica (NMO). NMO causes inflammatory 
demyelinating lesions primarily in the spinal cord and optic nerve, but also in the brain. This 
disease is characterized by serum autoantibodies directed against the astrocytic water 
channel aquaporin-4 (AQP4) (Lennon et al., 2005). NMO lesions are distinguished by a loss of 
AQP4, GFAP, as well as subsequent loss of oligodendrocytes leading to demyelinaton. 
Infiltration of granulocytes and macrophages as well as perivascular deposits of activated 
complement is found in the lesions. It is suggested that complement-dependent astrocyte 
cytotoxicity is involved in NMO leading to leukocyte infiltration, cytokine release and BBB 
disruption causing oligodendrocyte death as well as myelin loss (Lucchinetti et al., 2002; 
Misu et al., 2006). 
 
1.5.2 Astrocytic changes in EAE  
For a better understanding of MS and other diseases it is of high interest whether 
astrocytes have a detrimental or beneficial role after CNS injuries or after CNS defects. 
Therefore, generation of mice with altered GFAP expression provides a useful tool to study 
astrocytic changes in animal models of MS. Mice constitutively deficient for GFAP 
demonstrate a more severe disease course in EAE compared to wild type mice (Liedtke et al., 
1998). Furthermore, conditional inhibition of reactive astrocytosis by administration of 
ganciclovir in mice expressing the herpes simplex virus thymidine kinase under the mouse 
GFAP promoter results in more severe EAE and increased macrophage infiltration (Toft-
Hansen et al., 2011). Further studies investigating the role of astrocytes in wild type SJL/J 
mice with EAE report a down-regulation of connexin 43, the major gap junction protein of 
astrocytes, in inflamed white matter (Brand-Schieber et al., 2005). 
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1.6 The astrocytic leukodystrophy Alexander`s disease and its 
related animal model 
1.6.1 Alexander`s disease 
Alexander`s disease (AxD) is a rare and typically fatal disorder. Up to now, about 550 
cases of AxD have been reported. The disease was first characterized in 1949 by William 
Stewart Alexander who described a 15-month-old boy with a rapidly progressing 
neurological illness associated with a hydrocephalus (Alexander, 1949). AxD is classified as 
leukodystrophy since it mainly affects white matter accompanied by a severe myelin deficit 
particularly in the frontal lobes.  
Histological postmortem studies show extensive astrocytic inclusions known as 
Rosenthal fibers. These Rosenthal fibers, the pathological hallmark of AxD, are formed by 
cytoplasmic protein aggregates within astrocytes. These aggregates contain GFAP, vimentin, 
the cytoskeletal crosslinker plectin, ubiquitin, the small heat shock proteins 25 and αB-
crystallin (Iwaki et al., 1993; der Perng et al., 2006; Tian et al., 2006).  
The disease is divided in three forms based on the age of onset and the type of 
symptoms: Infantile, juvenile and adult form. The infantile type of the disease is the most 
aggressive, fatal and frequent form (80% of all cases) starting between the age of one month 
and two years. Clinical symptoms include progressive megalencephaly, seizures, progressive 
spastic paresis, mental regression, epilepsy, ataxia and hydrocephalus (Alexander, 1949; 
Borrett and Becker, 1985). The juvenile form (14% of all cases) starts between four to ten 
years of age. Patients typically suffer from dysphasia. Death ensues within several years after 
onset to the late teens with occasional longer survival. Almost all cases of infantile and 
juvenile AxD are sporadic. Adult cases are rare (6% of all cases). The adult form starts at the 
age of 20 to 45 years and symptoms can be similar to MS or the juvenile form (Seil et al., 
1968; Howard et al., 1993; Schwankhaus et al., 1995). The most frequent symptoms are 
related to bulbar dysfunction like dysarthria and dysphasia. It is the mildest type with longer 
survival times. However, rare familial cases of adult AxD have been reported showing a 
dominant or recessive mode of inheritance suggesting a genetic origin of the disease 
(Wohlwill et al., 1959; Honnorat et al., 1993; Howard et al., 1993; Schwankhaus et al., 1995).  
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AxD was the first human disorder found to be related to an isolated and genetically 
defined dysfunction of astrocytes. About 95% of AxD patients show mutations in the 
astrocytic intermediate filament GFAP (Brenner et al., 2001). These mutations are 
heterozygous and found within the human GFAP gene on chromosome 17q21 (Bongcam-
Rudloff et al., 1991). However, in rare cases of AxD no mutations in the GFAP coding region 
or adjacent introns have been found. More than 40 GFAP mutations have been reported, but 
over a third of all patients carry mutations in arginine residues in either of two amino acids, 
R79 (17% of all cases) or R239 (20% of all cases) (Prust et al., 2011). The most frequent 
mutations are heterozygous point mutations within the coding sequence (R79H, R239Cys, 
R239H) (Rodriguez et al., 2001; Li et al., 2005). The phenotype of R239 mutations results in 
more severe clinical disease than the mutation of the R79 site.  
The diagnosis of AxD involves MRI examination as well as genetic testing and only in 
rare cases a brain biopsy. Typical cases display widespread MRI changes involving extensive 
frontal white matter changes, periventricular changes as well as abnormalities of basal 
ganglia, thalami and brain stem (van der Knaap et al., 2001). However, in atypical cases of 
AxD the pathological examination of brain tissue at biopsy is necessary to confirm the 
diagnosis. However, most cases of AxD can be diagnosed by DNA analysis of PBMCs (Brenner 
et al., 2001). 
 
1.6.2 Human GFAP overexpressing transgenic mice 
Messing and colleagues generated and first described human GFAP overexpressing 
mice (Messing et al. 1998). The constitutively elevated expression of human GFAP in these 
animals is driven by the human GFAP promoter. The mice are hemizygous for the transgene 
and are generally viable and fertile. Only animals with very high levels of this transgene die 
within a few weeks after birth. Furthermore, the degree of overexpression increases with 
age. The homology between human and mouse GFAP is relatively high (91% identity and 
95% similarity at the amino acid level) (Brenner et al., 1990), but it seems likely that this 5% 
difference in amino acids together with the expression level contribute to the clinical and 
pathological changes observed in mice overexpressing human GFAP. 
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Astrocytes of mice overexpressing human GFAP show intracellular eosinophilic 
protein aggregates that appear histologically identical to Rosenthal fibers of AxD. The finding 
of Rosenthal fibers in brains of these transgenic animals led to the discovery of dominant 
GFAP mutations in AxD (Messing et al., 1998). Mice overexpressing human GFAP at levels 
approximately 3-5 fold over endogenous baseline levels show Rosenthal fibers and are 
further referred to as line 73.7 or Tg(hGFAP) animals in this thesis (Messing et al., 1998;   
Cho and Messing, 2009). Astrocytes of this transgenic line are also hypertrophic and           
up-regulate small heat shock proteins.  
Microarray analyses of the transcription profiles in these Tg(hGFAP) mice show 
marked immune and stress responses leading to an apparent loss of neurons or neuronal 
dysfunction in animals which are severely affected, but still viable (Hagemann et al., 2005). 
Differences in the astrocytic-neuronal interactions in distinct regions of these Tg(hGFAP) 
mice were reported (Meisingset et al., 2010). The authors of this study found an impaired 
astrocytic and neuronal metabolism in the cerebral cortex of these transgenic animals and a 
decreased transfer of glutamine from astrocytes to neurons compared to wild type mice. 
In the cerebellum of these Tg(hGFAP) animals, glutamine appeared increased and evidence 
for brain edema was found in an increased amount of brain water and the osmoregulators 
myo-inositol and taurine (Meisingset et al., 2010).  
In vitro studies of these Tg(hGFAP) mice indicate that astrocytes of these animals are 
more vulnerable and compromised than astrocytes of wild type mice. Astrocytes of these 
transgenic animals show an increased formation of cytoplasmic inclusions similar to 
Rosenthal fibers in 28% of GFAP-positive cells. Furthermore, these Tg(hGFAP) mice 
demonstrate a reduced astrocytic growth rate which is partially reflected by a decreased cell 
proliferation as well as an increased cell death of their cultured astrocytes. The proteasomal 
activity appears to be reduced by 35% compared to wild types and the cytoskeleton seems 
to be disrupted in these transgenic animals. Additionally, these Tg(hGFAP) mice show a 
compromised astrocytic resistance to stress which is indicated by an increased sensitivity to 
H2O2 (Cho and Messing, 2009). In the present thesis, only these Tg(hGFAP) mice (line 73.7 
with moderate overexpression of human GFAP) were used for the described experiments. 
 
 
                                                                                                                                                             1 Introduction 
20 
 
1.7 Aims  
The overall aim of the present study is to examine intrinsic and therapy-induced glial 
- in particular astrocytic - effects on cuprizone-induced pathology in mice. The first aim of 
the present work is to study the effects of LAQ on toxic demyelination. The second part 
intends to evaluate the impact of increased GFAP expression on cuprizone-induced changes. 
A further minor aim of this study is to assess the effects of cuprizone in vitro and in vivo. 
LAQ is a new oral immunomodulatory drug for MS that has well-documented effects 
on inflammation in the periphery, but up to now, little is known about its direct activity 
within the CNS. The aim of the first part of this work is to elucidate the impact of LAQ on 
CNS-intrinsic inflammation. Therefore, this project will investigate the effects of LAQ on 
cuprizone-induced de- and remyelination in vivo. To assess the effects on oligodendrocytes, 
apoptosis and oligodendroglial density will be evaluated in LAQ-treated and vehicle-treated 
wild type animals after one week of cuprizone. Demyelination, inflammation, axonal damage 
and glial pathology will be examined after six weeks of cuprizone treatment in LAQ-treated 
and vehicle-treated wild type mice. To test whether LAQ exerts effects independent of T and 
B cells, Rag1-deficient mice will also be treated with or without LAQ during cuprizone 
challenge. NF-κB activation in astrocytes will be investigated in LAQ-treated and vehicle-
treated animals. Remyelination will also be evaluated in LAQ-treated as well as vehicle-
treated wild type mice. Secondly, the effect of LAQ on demyelination will be also examined 
in a second model with focal rapid demyelination, the LPC-induced demyelination model.  
Mice overexpressing human wild type GFAP [Tg(hGFAP)] show an increased 
astrogliosis even without external stimuli. The aim of the second part of this work is to 
examine the impact of an increased astrogliosis on cuprizone-induced demyelination in vivo. 
Apoptosis and numbers of oligodendrocytes will be investigated in Tg(hGFAP) animals after 
one week of cuprizone. Demyelination, inflammation, axonal damage and glial pathology will 
be assessed after six weeks of cuprizone treatment in these mice. In addition, NF-κB 
activation in astrocytes will also be investigated in these transgenic animals.  
The third part of this work investigates direct effects of cuprizone on astrocytes in 
vitro and in vivo. First, the effect of cuprizone on astrocytic viability will be assessed in vitro. 
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Secondly, local effects of focal intracerebral cuprizone injection on myelin, oligodendrocytes 
and astrocytes will be evaluated in vivo.  
The overall aim of this study is to investigate intrinsic and therapy-induced astrocytic 
effects on cuprizone-induced pathology in mice. The findings from this project might 
contribute to a better understanding of the complex disease MS and enable the 
development of novel protective therapies restricting tissue damage in demyelinating 
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2 Materials and methods 
 
2.1 Materials and solutions 
2.1.1 Chemicals 
Chemicals      Provider 
Acetic acid, 10% solution   : Merck Millipore, Germany  
Agarose     : StarLab GmbH, Germany  
AgNO3 (silver nitrate)    : Carl Roth, Germany  
Ammonium chloride (10x)   : BD Biosciences, Germany 
Ammonia solution, 32%   : Merck Millipore, Germany  
Azure II, powder    : Merck Millipore, Germany  
Boric acid     : Carl Roth, Germany 
Di-sodium tetraborate decahydrate (borax) : Merck Millipore, Germany  
Chloral hydrate    : Fagron GmbH & Co. KG, Germany  
Citric acid     : Merck Millipore, Germany 
Cuprizone      : Sigma-Aldrich, Germany 
CuSO4 (copper(II) sulfate)   : Merck Millipore, Germany 
DAB (3,3'-diaminobenzidine)   : Sigma-Aldrich, Germany  
DAPI (4',6-diamidino-2-phenylindole) : Sigma-Aldrich, Germany 
DDSA (dodecenyl succinic anhydride) : Serva Electrophoresis, Germany 
DePeX mounting medium   : VWR International, Germany   
DMP-30 (2,4,6 tri(dimethylaminomethyl) : Serva Electrophoresis, Germany 
phenol) 
dNTP (desoxynucleoside triphosphate) mix : Fermentas, Germany  
DMEM [Dulbecco's modified eagle   : PAA laboratories, Germany 
medium) (High glucose (4.5 g/l)]  
Eosin G     : Merck Millipore, Germany 
Ethanol, 96%     : Merck Millipore, Germany  
Ethidium bromide    : Sigma-Aldrich, Germany   
EDTA (ethylenediamine tetraacetic acid  : Carl Roth, Germany 
disodiumsalt dihydrate) 
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Chemicals      Provider 
FCS (fetal calf serum)    : Biochrom AG, Germany  
Formalin (37% formaldehyde solution,  : Merck Millipore, Germany 
free from acid) 
GeneRulerTM, 100 base pairs (bp)  : Fermentas, Germany 
DNA ladder Plus 
Glutaraldehyde, 25% aqueous solution : Merck Millipore, Germany  
Ground mouse chow (complete feed for : Ssniff Spezialdiäten GmbH, Germany 
rats & mice-maintenance, ground) 
HBSS (Hank's buffered salt solution)  : Gibco, Germany  
HCl (hydrochloric acid)   : Merck Millipore, Germany  
Hydrogen peroxide, 30% solution  : Merck Millipore, Germany 
Isopropyl alcohol    : Merck Millipore, Germany 
Ketamine, 10%    : Inresa Arzneimittel GmbH, Germany  
LAQ (laquinimod) (ABR-215062)  : TEVA Pharmaceutical Industries, LTD,       
(RLB#054 M0004)      Israel 
LFB (luxol fast blue) : BDH Laboratory supplies, VWR Int. Ltd.,  
  Poole, UK) 
Lithium carbonate    : Merck Millipore, Germany  
LPS (lipopolysaccharide)   : Sigma-Aldrich, Germany 
Lysolecithin (L-α-lysophosphatidyl choline) : Sigma-Aldrich, Germany  
Mayers Hämalaun    : Merck Millipore, Germany  
Metapyrin, 500 mg/ml   : Serumwerk Bernburg AG, Germany  
Methylene blue    : Merck Millipore, Germany  
Monastral blue    : Sigma-Aldrich, Germany  
NaCl (sodium chloride), 0.9% solution : B. Braun Melsungen AG, Germany 
NaOH (sodium hydroxide solution), 1 M  : Merck Millipore, Germany  
Nitric acid, 65% solution   : Merck Millipore, Germany 
Osmium tetraoxide, powder   : Carl Roth, Germany  
Paraffin (paraplast plus)   : Tyco Healthcare, Germany    
PBS (Dulbecco’s phosphate-buffered saline): Biochrom AG, Germany 
10x powder 
PBS, sterile     : PAA laboratories, Germany 
PCR buffer, 5x  Green GoTaq Reaction  : Promega, Germany 
buffer  
Pen/strep (penicillin/streptomycin)  : Gibco, Germany 
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Chemicals      Provider 
Periodic acid     : Merck Millipore, Germany 
PFA (paraformaldehyde), powder  : Merck Millipore, Germany  
PLL (poly-L-lysine hydrobromide), powder : Sigma-Aldrich, Germany   
Renlam M-1     : Serva Electrophoresis, Germany  
Schiff`s reagent    : Sigma-Aldrich, Germany  
SDS (sodium dodecyl sulfate), 10% solution : Sigma-Aldrich, Germany  
Sodium thiosulfate pentahydrate  : Merck Millipore, Germany    
Tris      : Carl Roth, Germany  
Triton X-100     : MP Biomedicals, Germany  
Trypsin-EDTA (0.05% and 0.25% solution) : Gibco, Germany  
Trizma base     :  Sigma-Aldrich, Germany 
Xylazine (Xylariem)    : Riemser Arzneimittel AG, Germany 
Xylol      : Merck Millipore, Germany 
 
2.1.2 Enzymes/proteins  
Enzymes/proteins     Provider 
DNase I     : Roche, Germany 
ExtrAvidin peroxidase, 0.1% solution : Sigma-Aldrich, Germany 
Go-Taq DNA polymerase   : Promega, Germany  
IFNγ, recombinant    : R&D Systems, USA  
IL-1β, recombinant    : R&D Systems, USA 
Proteinase K     : Sigma-Aldrich, Germany  
TNFα, recombinant     : R&D Systems, USA 
 
2.1.3 Kits 
Kits       Provider 
CellTiter 96 Proliferation Assay  : Promega, Germany  
CytoTox-OneTM Assay    : Promega, Germany 




Consumables       Provider 
BD FalconTM cell culture flask, 75 cm2  : BD Biosciences, Germany 
BD FalconTM tube, 50 ml    : BD Biosciences, Germany 
Corning syringe filters, sterile   : Sigma-Aldrich, Germany 
Glass capillary, micropipettes 1-5 µl   : B. Braun Melsungen AG, Germany  
Glass microscope slides, 76x26 mm/3x1 inch : Knittel Glasbearbeitungs GmbH,  
Germany 
Neubauer counting chamber (surface 0.0025 mm2) : Brand GmbH, Germany  
Ocular counting grid, WHSZ 10X-H   : Olympus, Germany 
Petri dish      : Greiner Bio-One GmbH, Germany 
12-well tissue culture plates 665180, sterile : Greiner Bio-One GmbH, Germany 
96-well cell culture plates 655180, sterile  : Greiner Bio-One GmbH, Germany 
 
2.1.5 Technical devices 
Technical devices      Provider 
Camera for light microscope DP71   : Olympus, Germany 
Camera for fluorescence microscope XM10  : Olympus, Germany 
Cell incubator CWJ300DABA    : Cellstar, Nunc GmbH, Germany 
Centrifuge 5810 R     : Eppendorf, Germany 
Dental drill control tool K44974   : Kavo, Dental Excellence, Germany 
Dental drill 4912     : Kavo, Dental Excellence, Germany 
Fluorescence microscope BX51   : Olympus, Germany 
Inertsil ODS-4 chromatographic column  : GL Sciences, USA 
(3 µm, 75 x 2.1 mm equipped with guard column 
Inertsil ODS-4, 3 µm, 10 x 1.5 mm)  
Light microscope BX41    : Olympus, Germany 
Mass spectrometer TSQ Quantum Ultra AM : Thermo Finnigan, Germany  
Microtome SM2000R     : Leica, Germany 
Microwave NN-E201W    : Panasonic, Germany 
T3 Thermocycler     : Biometra, Germany  
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Technical devices      Provider 
Speed vacuum Concentrator 5301   : Eppendorf, Germany 
Stereotactic device STO-51730   : FMI GmbH-Stoelting, Germany 
Safire plate reader     : Tecan, Germany  
Tissue processor TP 1020    : Leica, Germany  
Thermo mixer comfort    : Eppendorf, Germany 
 
2.1.6 Solutions 
Chloral hydrate, 14% solution   : 14 g chloral hydrate 
        100 ml bidistilled water 
 
DAPI       : 1 µl DAPI  
        10,000 µl PBS 
 
Ketamine/xylazine mixture     : 1.2 ml ketamine 
1 ml xylazine    
7.8 ml NaCl    
 
Lysolecithin, 1% solution (Hall, 1972)  : 10 mg lysolecithin   
1 ml sterile PBS 
  
Metapyrin      : 3 ml Metapyrin 
        1 l water 
 
Monastral blue, 3% solution    : 0.3 g Monastral blue   
10 ml sterile PBS   
Filtration 
 
PFA, 4% solution     : 40 g PFA  
1,000 ml 1-fold PBS 
50 µl NaOH, adjust to pH 7.4 
Filtration 
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Tail lysis buffer      : 6.057 g Tris    
400 ml bidistilled water  
HCl, adjust to pH 8.5 
5 ml 5 mM EDTA   
20 ml 200 mM NaCl  
10 ml 0.2% SDS  
 
TBE buffer      : 10.8 g Tris    
5.5 g boric acid  
4 ml 0.5 M EDTA 
1,000 ml water   
      
 
Electron microscopy (EM) 
Glutaraldehyde, 3% solution    : 12 ml 25% glutaraldehyde  
88 ml PBS     
 
Richardson`s Stain (Richardson et al., 1960)  : 2 ml 1% Azure II  
        1 ml 2% Methylene blue  
        1 ml 1% Borax    
 
Synthetic resin      : 27 ml Renlam M-1  
        23 ml DDSA   
        0.75-1 ml DMP-30  
     
(Immuno-) histochemistry 
AgNO3, 20% solution     : 10 g AgNO3    
50 ml distilled water  
 
Citric acid buffer, 10 mM    : 2.1 g citric acid 
        1,000 ml distilled water 
        NaOH, adjust to pH 6 
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CuSO4 working solution     : 1 ml 2% CuSO4   
50 ml NaCl    
 
DAB working solution     : 49 ml PBS    
1 ml DAB    
20 µl hydrogen peroxide 
 
Developer stock solution     : 20 ml formalin  
0.5 g citric acid   
100 µl nitric acid   
500 ml distilled water  
 
Eosin, 1% solution     : 2 ml eosin     
198 ml 70% isopropyl alcohol,  
Filtration 
 
LFB working solution      : 1 g LFB  
 1 l ethanol 
5 ml acetic acid (add after 
complete solution of LFB) 
Filtration 
 
Sodium thiosulfate, 2% solution                                   : 10 g sodium thiosulfate 
pentahydrate 
500 ml distilled water 
 
Tris-EDTA, 1 mM     : 1.21 g Trizma base 
        1 ml 0.1 M EDTA 
        1,000 ml distilled water 
        Adjust to pH 8 
 
Triton, 1% solution     : 100 µl Triton X-100 
10 ml PBS  
    
    




DMEM+ working solution    : 500 ml DMEM    
50 ml inactivated FCS   




Software       Provider 
AnalysisTM       : Olympus, Germany  
GraphPad Prism     : GraphPad, California, USA 
SPSS 12      : IBM, Germany 
 
2.2 Animal experiments 
2.2.1 Mice 
8- to 10-weeks-old Tg(GFAP)10Mes, Rag1tm1Mom, and male C57BL/6J mice were used 
in these experiments. Tg(GFAP)10Mes animals overexpressing human GFAP and were from 
now on referred to as Tg(hGFAP). They were obtained on FVB/N genetic background and 
backcrossed to C57BL/6N. Their wild type littermates served as controls. Rag1tm1Mom mice 
lacking T and B cells and were from now on referred to as Rag1-/- animals. They were 
developed and first described by Mombaerts (Mombaerts et al., 1992). 
 
 
Mice      Provider 
C57BL/6J     Charles River, Germany 
Tg(hGFAP) (C57BL/6N background)  Animal facility of the University of Göttingen 
Rag1-/- (C57BL/6J background)  Animal facility of the University of Göttingen 
      Jackson Laboratories, USA 
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All mice were kept in groups up to 5 animals on a 12/12 hour (h) light/dark cycle with 
food and water ad libitum. Mice were acclimated to the new environment for at least 7 days 
before experiments were started. Animal experiments were conducted in accordance with 
the European Communities Council Directive of 24 November 1986 (86/EEC) and were 
approved by the Government of Lower Saxony, Germany. Each experiment contained 6-8 
mice per treatment group and was performed at least twice. The analyses of naïve 
Tg(hGFAP) and wild type mice were performed using 3-8 animals per group. 
 
2.2.2 Genotyping of transgenic mice 
2.2.2.1 DNA extraction 
For genotyping, DNA was extracted from tail or ear tissue of Tg(hGFAP) and Rag1-/- 
mice. Therefore, 350 µl tail lysis buffer containing 20 µl proteinase K was added to the tissue 
and digested over night in a thermo mixer at 350 rounds per minute (rpm) and 56°C. 
Digested tissue was centrifugated for 5 minutes (min) at 13,200 rpm at room temperature. 
Supernatant was transferred to a new tube and 350 µl isopropyl alcohol was added. 
Supernatant mixture was centrifugated again for 5 min at 13200 rpm at room temperature. 
Supernatant was rejected and pellet was washed with 350 µl 70% ethanol. After removing 
the supernatant by centrifugation, pellet was dried for 10 min by speed vac and then 
resuspended in 100 µl bidistilled water. 
 
2.2.2.2 Genotyping of Tg(hGFAP) mice 
Amplification of DNA in vitro was carried out by polymerase chain reaction (PCR). This 
reaction included 2 µl of the extracted DNA from mice as template, 1 µl 10 mM dNTP Mix,    
2 µl oligonucleotide primer (MB-114, Pr. 35, each 1 µl), 0.2 µl Go-Taq polymerase, 5 µl of the 
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Primer for Tg(hGFAP) Sequence     Provider 
MB-114   5’-CTC ATA CTC ATG ATG GGG AG-3’  Promega, Germany  
Pr. 35    5’-AAC AGC CTA TGG AGG GAC TG-3’ Promega, Germany  
 
All PCR reactions were run on a T3 thermocycler with cycle parameters listed below.  
95°C  180 seconds (s)  Pre-denaturation 
95°C  40 s    Denaturation 
62°C  30 s  35 cycles Annealing 
72°C  60 s    Elongation 
72°C  600 s    Final elongation 
4°C  ∞    Storage 
 
For visualization of PCR products, 10 µl of the probes were loaded on a 1.8% agarose 
gel (1.8 g agarose diluted in 100 ml TBE buffer) containing 3 µl ethidium bromide. 
Electrophoresis was performed at 100 Volt (V) for 60 min. One single PCR product of 381 bp 
labeled heterozygous Tg(hGFAP) mice (mice that are homozygous for the transgene are not 
viable). 5 µl of a 100 bp DNA ladder was used to estimate PCR product length. 
 
2.2.2.3 Genotyping of Rag1-deficient mice 
This reaction included 2 µl of the extracted DNA from mice as template, 1 µl 10 mM 
dNTP Mix, 3 µl oligonucleotide primer (oIMR1746, oIMR3104, oIMR8162, 1 µl each), 0.2 µl 
Go-Taq polymerase, 5 µl of the supplied buffer and 13.8 µl bidistilled water.  
 
Primer  for Rag1-/- mice Sequence     Provider 
oIMR1746   5’- GAG GTT CCG CTA CGA CTC TG-3’ Promega, Germany  
oIMR3104   5’- CCG GAC AAG TTT TTC ATC GT-3’  Promega, Germany 
oIMR8162   5’- TGG ATG TGG AAT GTG TGC GAG-3’ Promega, Germany 
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All PCR reactions were run on a T3 thermocycler with cycle parameters listed below.  
94°C  120 s    Pre-denaturation 
94°C  30 s    Denaturation 
58°C  45 s  35 cycles Annealing 
72°C  45 s    Elongation 
72°C  120 s    Final elongation 
4°C  ∞    Storage 
 
Probes were then loaded on an agarose gel and electrophoresis was performed as 
described above. One single PCR product at 530 bp labeled mice that are homozygous for 
the Rag1 mutation. Two PCR products of 530 bp and 474 bp (PCR product of wild type mice) 
labeled heterozygous Rag1 mice. A 100 bp DNA ladder was used to estimate PCR product 
length. 
 
2.2.3 Cuprizone treatment 
Cuprizone is a copper chelator and is known to induce toxic demyelination. At 8 to 10 
weeks of age, wild type C57BL/6J, Tg(hGFAP) and Rag1-/- mice received a 0.25% cuprizone 
diet ad libitum. Therefore, 2.5 g cuprizone was mixed into 1,000 g ground mouse chow.      
To investigate apoptosis, animals received cuprizone diet for 1 week. For studying effects on 
demyelination of the corpus callosum, mice were fed with cuprizone for 6 weeks.             
Body weights of animals were controlled once per week. Body weights of Tg(hGFAP) mice 
were converted in percent since transgenic animals were much smaller than their wild type 
littermates. The mean of the initial body weights of Tg(hGFAP) mice was set to hundred 
percent and the subsequent body weights of transgenic animals during cuprizone challenge 
were then converted in relation to the original weight at the beginning of the experiment. 
The same process was then applied for the body weights of wild type littermates. Graphs of 
body weights of wild type C57BL/6, Tg(hGFAP) and Rag1-/- mice were shown in mean values 
of body weight with standard errors of the mean (SEM). 
For investigating effects on remyelination in wild type C57BL/6, cuprizone diet was 
first fed for 6 weeks, cuprizone was then removed from the diet and mice were fed for the 
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following 4 days with ground mouse chow. Remyelination started after withdrawal of 
cuprizone. 
 
2.2.4 Extraction of mouse sera 
8-weeks-old male C57BL/6J mice received 0.25% cuprizone for 1 week. 9-weeks-old 
naïve male C57BL/6J animals served as controls. For mass spectrometry analyses, mice were 
sacrificed after 1 week of 0.25% cuprizone by i. p. injection of 200 µl 14% chloral hydrate 
solution. Blood samples were collected and serum was separated by centrifugation for        
15 min at 4°C and 1,000 rpm. The sera for mass spectrometry and in vivo and in vitro 
experiments were stored at -80°C. 
 
2.2.5 Laquinimod treatment 
LAQ was synthesized at TEVA Pharmaceutical Industries, Ltd. The compound was 
dissolved in water. The solution was stored at 4°C and used within 1 week of preparation. 
C57BL/6J mice were treated daily with 5 or 25 mg/kg LAQ. Rag1-/- mice were treated daily 
with 25 mg/kg. LAQ was administered orally by gavage at a volume of 0.2 ml. Control 
animals received vehicle (water). For investigating effects on cuprizone-induced 
demyelination, daily LAQ treatment was administered together with the cuprizone diet for   
1 week or 6 weeks. For investigating effects on remyelination, LAQ treatment started after 
withdrawal of cuprizone after 6 weeks and was carried out for the period of remyelination of 
4 days. For examining effects on LPC-induced demyelination, daily treatment with 25 or      
40 mg/kg LAQ started 3 days before stereotactic injection and was carried out until 4 days 
after injection. 
 
2.2.6 Intracerebral stereotactic injection 
C57BL/6J mice were first anaesthetized by i. p. injection of ketamine/xylazine mixture 
(100 µl/10 g body weight of mouse). After loss of consciousness, a rostro-caudal cut on the 
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top of the head was made to expose the skull. Animals were fixed on a stereotactic device.        
A fine hole was drilled through the scull 1 mm caudal and 2 mm sagittal to the bregma by a 
dental drill. To avoid damage to the brain, drilling was stopped until only a thin layer of bone 
was left. The remaining thin bone layer was then carefully removed by a fine scraper giving 
access to the brain surface. Monastral blue solution was added to the injection substances 
(LPC, cuprizone, PBS, serum from naïve or cuprizone-treated mice) to mark the injection site. 
This mixture was inserted stereotactically into the corpus callosum by a finely calibrated 
glass capillary. The injection substances were slowly administered to avoid tissue damage. 
After injection the capillary was carefully removed and the skin was sutured. For pain 
therapy, animals were treated with Metapyrin. Metapyrin administration started 1-2 days 
before and was carried out for 2 days after stereotactic injection. 
 
2.2.6.1 Focal demyelination induced by lysolecithin 
LPC is a membrane-solubilizing agent which is toxic especially for myelin. At 9 to 10 
weeks of age male C57BL/6J mice were intracerebrally, stereotactically injected with 1 µl 1% 
LPC into the corpus callosum to induce focal demyelination. LPC was diluted in sterile PBS. 
Controls were injected with PBS (vehicle). Animals were sacrificed 4 days after injection. 
Experiments investigating the effect of 25 mg/kg LAQ on LPC-induced demyelination 
were performed using 7 mice in the control group and 5 animals in the LAQ group. 
Experiments evaluating the effect of 40 mg/kg LAQ on LPC-induced demyelination were 
performed using 3 mice in the control group and 4 animals in the LAQ group. 
 
2.2.6.2 Stereotactical injection of cuprizone or serum 
To test for potential direct effects of cuprizone or serum after focal cerebral 
administration, 1 µl of one of the following four agents were injected stereotactically into 
the corpus callosum of 9- to 10-weeks-old male C57BL/6J mice. Animals received 
stereotactic injections of either (1) 200 µM cuprizone diluted in sterile PBS, (2) vehicle (PBS), 
(3) pure serum from cuprizone-treated mice to examine whether a metabolite of cuprizone 
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leads to cuprizone-induced pathology or (4) pure serum from 9-weeks-old naïve male 
C57BL/6J animals.  
All mice were sacrificed 4 days after stereotactic injection. Experiments with each 
agent were performed with at least 3 animals for the four different groups. 
 
2.3 Histology 
After completion of experiments, mice were injected i. p. with a lethal dose of 14% 
chloral hydrate solution. After loss of consciousness and protective reflexes, transcardial 
perfusion was performed through the left heart ventricle with PBS followed by 4% PFA. 
Brains, livers and spleens were collected and stored in 4% PFA at 4°C for 2 days post-fixation. 
Then tissue samples were transferred in PBS. For cuprizone experiments, brains were 
dissected in at least 4 transverse sections. For stereotactical injections, one brain section 
including the injection site was cut following the Monastral blue trace. For paraffin 
embedding, tissue was washed in water and then gradually dehydrated over night by 
performing a graded alcohol/xylene/paraffine series using an automated tissue processor. 
Histological evaluation was performed on 1 µm thick sections using a sliding microtome.  
Prior the staining procedure tissue sections were deparaffinized for at least 30 min at 
54°C and rehydrated. Rehydration steps were done as follows:  
4x 10 min  xylol 
1x   5 min  isoxylol    
2x   5 min  100% isopropyl alcohol 
1x   5 min  90% isopropyl alcohol 
1x   5 min  70% isopropyl alcohol  
1x   5 min  50% isopropyl alcohol  
Distilled water 
 
After the staining procedure, stained sections were dehydrated by performing above 
descriped series in reversed order with only 2-3 min incubation time to avoid excessive 
weakening of the staining. Finally, stained sections were mounted in DePex medium. 
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2.3.1 Histochemical staining 
2.3.1.1 Hematoxylin and eosin (HE) staining 
For a general overview of the sections, HE staining was performed especially with 
regard to inflammation and apoptosis. Rehydrated sections were incubated for 8 min in 
Mayers Hämalaun. Tissue sections were then incubated shortly in 1% HCl and were washed 
in distilled water for differentiation of the tissue. Bluing was done by rinsing slides in running 
water for 10 min. Slides were incubated shortly in distilled water and transferred in 1% eosin 
solution for 6 min. 
 
2.3.1.2 Luxol fast blue-periodic acid Schiff (LFB-PAS) staining 
To assess the extent of demyelination, LFB-PAS staining was performed. After the 
90% isopropyl alcohol rehydration step, sections were incubated in LFB working solution at 
60°C over night. Next day, tissue sections were washed with 90% isopropyl alcohol. For 
differentiation, the following 3 steps were repeated until only the myelin was stained deep 
blue: Sections were first incubated shortly in 0.05% lithium carbonate (diluted in water), 
incubated shortly in 70% isopropyl alcohol and then washed extensively in distilled water to 
stop differentiation. Stained sections were transferred in 1% periodic acid (diluted in water) 
for 5 min and then washed thoroughly in distilled water. Sections were stained in Schiff`s 
reagent for 20 min. Slides were washed under running water for 10 min. Counterstaining 
was performed by transferring tissue sections for 3 min in Mayers Hämalaun. Slides were 
washed in distilled water and incubated shortly in 1% HCl. After washing shortly in distilled 
water, bluing was achieved by rinsing slides in running water for 10 min.  
 
2.3.1.3 Bielschowsky silver impregnation 
Bielschowsky silver impregnation was performed to investigate axonal integrity. 
Rehydrated sections were transferred in AgNO3 solution and incubated for 20 min.        
Tissue sections were washed with distilled water. Ammonia solution was added drop by drop 
to the AgNO3 solution until the formed precipitation cleared up. Sections were transferred in 
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this cleared mixture and incubated in the dark for 15 min. Slides were then transferred in   
50 ml bidistilled water containing 150 µl ammonium chloride. 500 µl developer stock 
solution was then added to the AgNO3/ammonium chloride solution which was used 
previously. Slides were transferred in this solution for about 3 to 5 min until the axons were 
stained black and the color of the tissue turned to ochery. Tissue slides were washed in 
bidistilled water and transferred in 2% sodium thiosulfate solution for 2 min.  
 
2.3.2 Immunohistochemistry and fluorescence staining 
Immunohistochemistry was performed with antibodies against activated microglia 
(Mac3), acutely damaged axons (amyloid precursor protein; APP), GFAP (polyclonal),    
mature oligodendrocytes (NogoA), MBP, CNPase and apoptosis (active caspase3). 
Immunofluorescence staining involved antibodies against NF-κB and GFAP (monoclonal). 
Tissue sections were pre-treated by heating 10 mM citric acid buffer or 1 mM Tris-EDTA 
buffer in a microwave for 5 times (3 min each). Therefore, tissue sections were transferred in 
glass cuvettes filled with corresponding buffer. Glass cuvettes were then refilled alternately 
after each microwave step with distilled water or corresponding buffer to dilute buffer.     
For staining against the polyclonal GFAP antibody, sections were only washed in PBS instead 
of pre-treatment in a microwave. To block endogenous peroxidase, all sections were first 
washed in PBS and then incubated for 20 min in 3% hydrogen peroxide solution at 4°C.   
After 3 washing steps with PBS, sections were blocked for 20 min with 10% FCS in PBS at 
room temperature to inhibit unspecific antibody binding. Caspase3 staining required 
treatment with 1% Triton solution for 1 h instead of FCS. Primary antibodies (Tab. 1) were 
diluted in 10% FCS in PBS and incubated over night at 4°C in a wet chamber. Control sections 
were incubated in the absence of primary antibody or with isotype control antibodies. 
Sections were then washed in PBS for 3 times. For fluorescence double-labeling, bound 
antibody was visualized with Streptavidin cyanine (Cy)3-conjugated goat-anti rabbit IgG and 
Cy2-conjugated goat-anti-mouse IgG. Additionally, DAPI was used to counterstain the nuclei.  
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Tab. 1: Primary antibodies for immunohistochemistry and fluorescence staining 
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For immunohistochemistry, antibody binding of biotin-conjugated secondary 
antibodies was visualized by using peroxidase and DAB. Biotinylated secondary antibodies 
(Tab. 2) were diluted in 10% FCS in PBS. After 1 h of incubation, remaining unbound 
antibodies were removed by washing with PBS. Slides were transferred for 1 h in peroxidase 
                                                                                                                                         2 Materials and methods 
39 
 
(diluted in 10% FCS in PBS) at room temperature. After washing with PBS for 3 times, the 
unbound peroxidase was removed. DAB working solution was used to visualize the antibody 
binding. DAB was oxidized by the bound peroxidase developing a brown staining. 
Additionally, caspase3 staining was amplified with CuSO4 working solution. Slides were 
counterstained with hemalaun.  
 
Tab. 2: Secondary antibodies for immunohistochemistry and fluorescence staining 
Antibody Host Directed against Dilution Provider 
Goat anti-rabbit IgG (H+L)-
Biotin  
Goat Anti-rabbit 1:500 Dianova 
Biotinylated anti-mouse Ig Sheep Anti-mouse 1:200 Amersham 
Biosciences 
Streptavidin Cy3 Goat Anti-rabbit IgG 1:100 Jackson 
ImmunoResearch 




2.4 Electron microscopy (EM) 
In a subset of animals (n = 5 per group), electron microscopic analysis of the corpus 
callosum was carried out to confirm the extent of demyelination. Mice treated with 0 and  
25 mg/kg LAQ were sacrificed after 6 weeks of cuprizone feeding. Therefore, animals were 
injected i. p. with a lethal dose of 14% chloral hydrate solution. After loss of consciousness 
and protective reflexes, transcardial perfusion was performed through the left heart 
ventricle with PBS. The corpora callosa were collected and stored in 3% glutaraldehyde at 
4°C for at least 7 days post-fixation. Para-sagittal slices of 1 mm thickness were obtained 
from the corpus callosum. Sections were processed through osmium tetraoxide, dehydrated 
and embedded in synthetic resin. Ultrathin sections were then cut for electron microscopy. 
Semi thin sections were stained with Richardson`s Stain and evaluated by light microscopy. 
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2.5 Morphometry and data acquisition 
To evaluate the extent of demyelination in the corpus callosum of each animal,     
LFB-PAS stained sections after 6 weeks of cuprizone were analyzed using a semi quantitative 
scoring system: No demyelination (0), minimal demyelination (0.5), < 33% demyelination (1), 
33% - 66% demyelination (2), and > 66% demyelination (3). GFAP-stained sections were also 
investigated semi quantitatively after 6 weeks of cuprizone using the following scoring 
system: No reactive astrogliosis (0), minimal astrogliosis (1), moderate astrogliosis (2) or 
severe reactive astrogliosis (3). APP-positive axons and Mac3-positive microglia were also 
examined after 6 weeks of cuprizone. NogoA-positive oligodendrocytes, HE-stained and 
caspase3-positive apoptoses were assessed after 1 week of cuprizone. Apoptotic cells were 
identified by a pyknotic nucleus or apoptotic bodies as well as eosinophilic cytoplasm. 
NogoA-positive oligodendrocytes were also evaluated after 4 days of remyelination.          
The density of axons and cells were determined by counting stained axons and cells in the 
corpus callosum using a light microscope at 400x magnification and an ocular counting grid.  
Immunofluorescent pictures were taken of the corpus callosum to assess the 
proportion of GFAP-positive astrocytes with nuclear NF-κB p65 translocation after 6 weeks 
of cuprizone. The total number of GFAP positive astrocytes were determined as well as the 
number of GFAP positive astrocytes with nuclear p65 signal to calculate the percentage of 
GFAP-positive cells with nuclear p65 translocation.  
For investigating the lesion size of LPC-induced demyelination, images were taken at 
a 100x original magnification and further processed using the software AnalysisTM.  
All histological quantifications were carried out in a blinded manner. For 
representation of the results graphs were generated by GraphPad Prism software. 
 
2.6 Mass spectrometry analysis 
To measure cuprizone concentrations in brain and plasma, brain and plasma samples 
were frozen on dry ice, stored at -80°C and send to Dr. Marta Patfalusi (Aurigon-Toxicoop 
Research Center, Department Analytics, Budapest, Hungary).  
Cuprizone was then quantified in brain and plasma samples by reverse phase high 
performance liquid chromatography (HPLC) with mass spectrometer detection. For brain 
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samples, 40 µl of 1 µg/ml freshly prepared internal standard solution (omeprazole) and 2 ml 
of chloroform:acetonitrile (1:1) v/v (each volume) mixture were added to the frozen mouse 
brain and homogenized immediately by an ultrasonic homogenizer for 5-10 s. The sample 
was then mixed followed by centrifugation at 6,000 rpm for 10 min at 5°C. 5 µl of the organic 
phase was injected onto the HPLC column.  
For plasma samples, 50 µl of mouse plasma were added to 10 µl of 1 µg/ml freshly 
prepared internal standard solution (omeprazole), 10 µl of acetonitrile and 200 µl of 
chloroform. The solution was thoroughly mixed by vortexing followed by centrifugation at 
10,000 rpm for 5 min at 5°C. 200 µl volume of the lower phase was then transferred into  
200 µl of acetonitrile. 5 µl of the solution was injected onto the HPLC column. 
For both brain and plasma samples, the chromatographic separation was performed 
by gradient elution on an Inertsil ODS-4 chromatographic column. Mass spectrometer 
analysis was performed using a TSQ Quantum Ultra AM mass spectrometer in positive 
ionization mode. The following multiple reaction monitoring (MRM) transitions were 
monitored: Mass-to-charge ratio (m/z) 279.2 → 139.1 for cuprizone and 346.1 → 198.0 for 
omeprazole.  
Mass spectrometry analyses of brain and plasma samples of wild type C57BL/6J and 
Tg(hGFAP) mice were performed at least twice (2 independent experiments) with at least     
5 animals per group. Many plasma samples showed cuprizone levels below the limit of 
quantification and had to be excluded from the statistical analyses. Therefore, the presented 
data on plasma samples with detectable cuprizone plasma levels included a minimum of 
only 3 mice per group. Graphs showing spectrometric data show mean values with the 
corresponding standard deviation. 
 
2.7 Primary cell cultures 
2.7.1 Isolation of primary astrocytes from newborn mice 
Newborn C57BL/6J mice (p0 or p1) were decapitated. Heads were transferred to a 
Petri dish with cold HBSS medium to rinse off the blood. The skull was opened and brains 
were transferred into fresh HBSS. Cerebella were removed and discarded. Meninges of 
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cerebrums were removed to prevent that meningeal fibroblasts interfere with the glial cell 
growth. Isolated cerebrums were transferred in a 50 ml Falcon tube filled with HBSS and 
stored on ice. After preparation, HBSS was removed and cells were isolated by incubating 
the brains in 0.25% Trypsin-EDTA (2 ml per brain) mixed with DNase (33.33 µl per brain) for 
10 min and 37°C. After washing with 10 ml HBSS brains were transferred in 5 ml DMEM+.     
A cell suspension was prepared by mechanical dissociation of brains in DMEM+ with first a 
10 ml pipette and second a 1,000 µl pipet tip. The cell suspension was filled in PLL-coated 
cell culture flasks containing 10 ml DMEM+ (ca. 2 to 3 brains per flask). The primary culture 
including astrocytes, oligodendrocytes and microglia was cultivated for 7 to 10 days in a 
tissue culture incubator at 37°C and 5% CO2. Medium was changed every 3 to 4 days. 
After 7 to 10 days of cultivation, mixed glial cell cultures were shaken vigorously to 
remove most of oligodendrocytes and microglia. The medium containing detached cells was 
removed and remaining cells in culture flasks were washed with PBS twice. 5 ml 0.05% 
Trypsin-EDTA was added to remaining astrocytes for 2 to 3 min to detach cells. The reaction 
was stopped by adding 10 ml DMEM + 10% FCS. Cell suspension was transferred to a 50 ml 
Falcon tube and centrifuged for 10 min at 900 rpm to remove EDTA and isolate astrocytes. 
Supernatant was discarded and the cell pellet was resuspended in DMEM+. The number of 
astrocytes was determined in a Neubauer counting chamber. For the cell viability and 
membrane integrity assay, astrocytes were plated at a density of 10,000 cells per well in a 
96-well-plate coated with PLL. For the migration assay, astroyctes were plated at a density of 
200,000 cells per well in a PLL-coated 12-well-plate. Before starting experiments astrocytes 
were incubated in DMEM+ for at least 48 h to ensure differentiation of astrocytes.              
For cuprizone treatment, 1 µM, 10 µM or 100 µM cuprizone (diluted in DMEM+) were added 
to the cells. For serum treatment, 10% serum from cuprizone-treated mice or 10% serum 
from naïve mice (each diluted in DMEM+) was added to astrocytes. Astrocytes were treated 
for 24 h with cuprizone or serum. Untreated cells served as controls. Each group was 
measured in triplicates. 
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2.7.2 Cell viability assay (MTT assay) 
To assess mitochondrial respiration after treatment with cuprizone or serum, the 
CellTiter 96 Non-Radioactive Cell Proliferation Assay was used. Therefore, supernatant was 
removed after treatment with cuprizone or serum and fresh DMEM+ was added to the cells. 
15 µl of the Dye Solution was added to each well. The 96-well plate was incubated at 37°C 
and 5% CO2 for 4 h. 100 µl of the Solubilization Solution/Stop Mix was then added to each 
well and incubated for 1 h. Each well was then mixed slightly. Absorbance was recorded at 
570 nm wavelength and a reference wavelength at 650 nm to reduce background using a 
Tecan Safire plate reader. Mitochondrial respiration was converted to percent since the 
measured values differed in their baseline levels. Hence, the mean of mitochondrial 
respiration of control condition was set to hundred percent and the treatment conditions 
were expressed in relation to the control group. Cell viability assays were performed at least 
3 times with at least 2 wells per treatment condition. 
 
2.7.3 Membrane integrity assay 
The amount of astrocytic cell damage was examined after treatment with cuprizone 
or serum by using the CytoTox-OneTM Homogenous Membrane Integrity Assay. 100 µl of 
CytoTox-OneTM Reagent was added to each well and incubated for 10 min at 22°C. 50 µl of 
the Stop Solution was then added to each well. The 96-well-plate was shaken slightly for     
10 s. Fluorescence was recorded with an excitation wavelength of 560 nm and an emission 
wavelength of 590 nm using a Tecan Safire plate reader. The membrane integrity assay was 
performed 3 times with at least 2 wells per treatment condition. 
 
2.7.4 Migration assay 
To test for the ability of astrocytes to migrate into a cell-free area, a migration assay 
was performed. After grown to a confluent cell monolayer, the cell monolayer was scraped 
in a straight line with a 200 µl pipet tip to create a scratch as a cell-free area (Liang et al., 
2007). The cellular debris was removed by washing twice with culture medium. A reference 
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point was created by etching the outer bottom of the dish slightly with a razor blade.      
After treatment with cuprizone or serum, the dish was placed in a tissue culture incubator at 
37°C and 5% CO2. Representative images were taken after 0, 24 and 42 h. Migration assays 
were performed 3 times with at least 2 wells per treatment condition. 
 
2.8 Statistical analysis 
Statistical analyses were carried out using the software package SPSS. Histological 
differences between vehicle and LAQ-treated or wild type and transgenic mice were 
analyzed by Mann-Whitney-U tests for nonparametric data. Statistical significance was 
defined as p < 0.05. 
Parametric data were analyzed by independent t tests as follows: For the subsequent 
analyses of astrocytic NF-κB activation in both LAQ and Tg(hGFAP) experiments, effect of 
cuprizone or serum on mitochondrial respiration and cell damage in primary astrocytes. 










3.1 Evaluating the effect of LAQ on toxic de- and remyelination in 
mice 
3.1.1 Reduced cuprizone-induced weight loss and oligodendroglial apoptosis 
under LAQ in wild type mice 
The effect of preventive treatment with 25 mg/kg LAQ was examined after cuprizone 
treatment. Clinical and histological analyses were performed to assess vehicle- and LAQ-
treated mice. Body weights of both groups were evaluated after each week of cuprizone 
treatment. After one week of 0.25% cuprizone, vehicle-treated controls showed substantial 
weight loss, whereas LAQ-treated animals showed no weight loss (Fig. 2). During the 
following five weeks of cuprizone challenge, LAQ-treated mice always displayed significantly 





The effects of LAQ treatment on cuprizone-induced pathology were first determined 
after one week of cuprizone challenge to investigate whether LAQ affects oligodendrocyte 
survival. At this time point, oligodendroglial apoptosis is typically observed (Hesse et al., 
2010). Apoptotic cells were first visualized morphologically on HE-stained sections and then 
stained for active caspase3, a marker for cells undergoing apoptosis. Vehicle-treated mice 
Fig. 2: No weight loss under LAQ 
treatment during 6 weeks cuprizone 
challenge. Vehicle-treated controls and 
mice treated with 25 mg/kg LAQ at 
weeks 0-6 during 0.25% cuprizone 
challenge. During the 6 weeks of 
cuprizone treatment, animals treated 
with LAQ show significantly higher body 
weights than vehicle-treated mice    
(***p < 0.001). 
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showed numerous apoptosis in the corpus callosum (Fig. 3A) whereas LAQ-treated animals 




Fig. 3: Decreased cuprizone-induced oligodendroglial apoptosis under LAQ treatment. Evaluation of 
apoptotic cells and oligodendrocytes after 1 week of 0.25% cuprizone in vehicle- (A, D, G) and LAQ-
treated mice (B, E, H). Vehicle group (A) shows significantly more HE-stained apoptotic cells 
(arrowheads) in the corpus callosum than LAQ group (B, C) (**p < 0.01). Density of apoptotic cells 
stained positively for active caspase3 (arrowheads) are significantly higher in vehicle-treated (D) 
compared to LAQ-treated animals (E, F) (***p < 0.001). NogoA-positive oligodendrocytes 
(arrowheads) are detected in both groups (G, H). The density of mature oligodendrocytes is similar in 
LAQ- and vehicle-treated mice (I) (p > 0.05). Oligodendrocytes are positive for CNPase (red 
arrowhead) (J). Only scattered apoptotic cells are CNPase-positive (black arrowhead) indicating that 
these apoptotic cells are oligodendrocytes. Representative images of the medial part of the corpus 
callosum were taken at 400x original magnification (scale bars: 50 µm) (A-H) or at 1,000x original 
magnification (scale bar: 10 µm) (J). Inserts show magnified representative cells.  
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The quantitative analysis revealed that the density of apoptotic cells was significantly 
lower in mice treated with LAQ (52 ± 38 apoptoses per mm2) in comparison to controls 
treated with vehicle (109 ± 28 apoptoses per mm2; p < 0.01) (Fig. 3C).  
Compared to vehicle-treated animals (Fig. 3D) the number of caspase3-positive 
apoptotic cells was significantly reduced in the corpus callosum of LAQ-treated mice (98 ± 28 
vs. 37 ± 26 caspase3-positive apoptosis per mm2; p < 0.001) (Fig. 3E, F). 
To investigate mature oligodendrocytes, immunohistological stainings for the 
oligodendroglial marker NogoA were performed. NogoA-positive mature oligodendrocytes 
were detected in the callosal white matter of both groups. Quantitative evaluation revealed 
that numbers of mature oligodendrocytes were slightly, but not significantly higher in LAQ- 
(598 ± 25 NogoA-positive cells per mm2) (Fig. 3H) compared to vehicle-treated mice (570 ± 
25 NogoA-positive cells per mm2; p > 0.05) (Fig. 3G, I). Scattered apoptotic cells were 
immunopositive for CNPase identifying these apoptotic cells as oligodendrocytes (Fig. 3J). 
 
3.1.2 Dose-dependent inhibition of cuprizone-induced demyelination by LAQ 
To assess whether preventive treatment with 5 and 25 mg/kg LAQ exerts effects on 
cuprizone-induced demyelination, mice were treated for six weeks with cuprizone. 
Demyelination was investigated in the corpus callosum of both groups. Vehicle-treated mice 
displayed extensive demyelination in the corpus callosum (Fig. 4A, D) whereas animals 
treated with 25 mg/kg LAQ showed reduced demyelination (Fig. 4C, F). Mice given the lower 
dose of 5 mg/kg LAQ showed moderate demyelination of the corpus callosum (Fig. 4B, E). 
Furthermore, vehicle-treated controls showed a moderate increase of cell density in the 
callosal white matter in comparison to LAQ-treated animals (Fig. 4D, F). More PAS-positive 
microglia were observed in vehicle-treated controls (Fig. 4D). The semi quantitative 
assessment of demyelination in the corpus callosum revealed significantly higher 
demyelination in vehicle-treated mice (score 2.4 ± 0.5) than in animals treated with the 
lower (score 1.8 ± 0.8) and higher dose of LAQ (score 0.6 ± 0.3; p < 0.001) (Fig. 4G). Mice 
treated with 5 mg/kg LAQ displayed significantly more demyelination than animals treated 
with 25 mg/kg (p < 0.01) (Fig. 4G). LAQ-treated mice also displayed less demyelination in 
other brain areas such as the cortex and cerebellum (data not shown).  
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Electron microscopic evaluation demonstrated numerous demyelinated axons in the 
corpus callosum of vehicle-treated controls and only little signs of remyelination (Fig. 4H).   
In contrast, animals treated with 25 mg/kg LAQ showed only scattered demyelinated axons 
and many intact myelin sheaths (Fig. 4I).  
 
 
Fig. 4: Callosal demyelination is reduced in a dose-dependent manner under LAQ after 6 weeks of 
cuprizone. Vehicle-treated controls show extensive demyelination (A, D), while mice treated with     
5 mg/kg LAQ show moderate (B, E) and animals treated with 25 mg/kg LAQ show minimal 
demyelination (C, F). The semi quantitative evaluation of demyelination (G) reveals significantly more 
demyelination in vehicle-treated controls than in both LAQ groups. Mice treated with 25 mg/kg LAQ 
demonstrate significantly less demyelination than animals treated with 5 mg/kg LAQ (**p < 0.01; 
***p < 0.001). Representative electron microscopic images show many demyelinated axons and 
single remyelinated axons in vehicle-treated mice (H). In contrast, animals treated with 25 mg/kg 
LAQ show many intact myelin sheaths with almost no signs of demyelination (I). Scale bars: A-C 
500 µm, D-F 50 µm, H-I 2 µm.  
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3.1.3 Decreased cuprizone-induced microglial activation, axonal damage and 
astrogliosis by LAQ 
The effect of LAQ on activated microglia was determined by evaluating Mac3-positive 
cells in the corpus callosum after six weeks of cuprizone. Mac3 staining revealed more 
activated microglia cells in vehicle-treated animals (Fig. 5A) than in mice treated with          
25 mg/kg LAQ (Fig. 5B). Quantitative analysis of the microglia density within the corpus 
callosum demonstrated significantly reduced numbers of microglia under LAQ (185 ± 84 
Mac3-positive cells per mm2) compared to vehicle treatment (1000 ± 298 Mac3-positive cells 
per mm2; p < 0.001) (Fig. 5C).  
 
 
Fig. 5: LAQ treatment reduces cuprizone-induced microglial activation, axonal damage and gliosis. 
LAQ-treated mice display less microglial activation (A-C), axonal damage (D-F) and fibrillary gliosis  
(G-I) after 6 weeks of 0.25% cuprizone. The density of Mac3-positive activated microglia 
(arrowheads) is significantly higher in vehicle-treated animals (A) compared to LAQ-treated mice     
(B, C) (***p < 0.001). Inserts show magnified representative cells. APP-positive axonal spheroids 
(arrowheads) are significantly higher in vehicle-treated (D) compared to LAQ-treated animals (E, F) 
(***p < 0.001). The density of GFAP-positive glial fibers is significantly higher in the vehicle (G) than 
in the LAQ group (H, I) (**p < 0.01). Representative images of the medial part of the corpus callosum 
were taken at 400x original magnification (scale bars: 50 µm).  
                                                                                                                                                                      3 Results 
50 
 
To examine the effect of LAQ on axonal integrity, acutely damaged axons characterized 
by accumulation of APP were analyzed. Vehicle-treated animals showed numerous damaged 
axons (Fig. 5D) whereas APP-positive axons were nearly absent in mice treated with             
25 mg/kg LAQ (Fig. 5E). The quantitative analysis revealed a significant reduction of acute 
axonal damage under LAQ treatment (5 ± 3 APP-positive axons per mm2) in comparison to 
vehicle-treated controls (173 ± 111 APP-positive axons per mm2, p < 0.001) (Fig. 5F). 
To investigate whether LAQ treatment affects astrocytes, reactive astrogliosis was 
assessed semi quantitatively by staining with an antibody against GFAP. Reactive astrogliosis 
was prominent in the corpus callosum of vehicle-treated animals (score 2.6 ± 0.5) (Fig. 5G) 
whereas GFAP stained astrogliosis was reduced in mice treated with 25 mg/kg LAQ (score 
1.3 ± 0.5) (Fig. 5H). The semi quantitative analysis confirmed a significant reduced fiber 
gliosis in the LAQ group compared to the vehicle group (p = 0.001) (Fig. 5I). 
 
3.1.4 Similar cerebral cuprizone concentrations in mice treated with LAQ and 
vehicle  
To investigate whether cuprizone levels were comparable in both groups, cuprizone 
concentrations were measured in brains after one week (Fig. 6A) and six weeks (Fig. 6B) of 




Fig. 6: Similar cuprizone concentration in brains of LAQ- and vehicle-treated mice after 1 week and 
6 weeks of cuprizone. After 1 week (A) and 6 weeks (B) of 0.25% cuprizone treatment, cuprizone was 
quantified in brain samples of 25 mg/kg LAQ- and vehicle-treated mice by RP-HPLC mass 
spectrometry analysis. Cuprizone concentrations are similar for both treatment regimes at both time 
points (p > 0.05).  
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Mass spectrometry analyses revealed that the cerebral cuprizone concentrations did 
not differ significantly between vehicle- and LAQ-treated mice after one week (136 ± 150 
ng/g brain tissue for the vehicle group and 190 ± 242 ng/g brain tissue for the LAQ group) 
and after six weeks of cuprizone (51 ± 43 ng/g brain tissue for the vehicle group, 84 ± 89 
ng/g brain tissue for the LAQ group).  
To determine whether cuprizone levels in serum were also comparable in both 
groups, mass spectrometry analyses were performed after one week cuprizone challenge 
(Fig. 7). Cuprizone concentrations in plasma were very low in both groups and did not show 
any significant differences between both groups after one week (2 ± 1 ng/ml plasma for the 




3.1.5 Reduced cuprizone-induced pathology under LAQ also in Rag1-deficient 
mice 
To determine whether the effects of LAQ treatment are independent of T and B cells, 
Rag1-/- mice lacking T and B cells were treated with vehicle or 25 mg/kg LAQ during 
cuprizone feeding for six weeks. The results were similar to findings in wild type mice: LAQ-
treated Rag1-/- mice displayed significantly higher body weights compared to corresponding 
vehicle-treated Rag1-/- animals (Fig. 8).  
 
Fig. 7: Low cuprizone concentration in plasma of LAQ- and 
vehicle-treated mice after 1 week of cuprizone. After          
1 week of 0.25% cuprizone treatment, cuprizone was 
quantified in plasma samples of 25 mg/kg LAQ- and vehicle-
treated mice by RP-HPLC mass spectrometry analysis. 
Cuprizone concentrations are similar for both treatment 
regimes in plasma (p > 0.05).  






After six weeks of cuprizone, vehicle-treated mice showed extensive demyelination 
(Fig. 9A) whereas LAQ-treated Rag1-/- animals displayed reduced demyelination in the corpus 
callosum (Fig. 9B). Semi quantitative analysis revealed significantly lower demyelination 
scores in LAQ-treated Rag1-/- mice (score 0.5 ± 0) compared to vehicle-treated Rag1-/- 
animals (score 2.4 ± 0.5; p < 0.001) (Fig. 9C).  
 
 
Fig. 9: Reduced demyelination, activated microglia, acute axonal damage and astrogliosis in LAQ-
treated Rag1-/- mice compared to vehicle-treated controls after 6 weeks of cuprizone. Compared 
to vehicle-treated Rag1-/- mice (A) LAQ-treated Rag1-/- mice (B) show significantly less demyelination 
on LFB-PAS-stained sections (***p < 0.001). The density of callosal microglia (arrowheads) is higher in 
vehicle-treated Rag1-/- mice (D) than in the LAQ group (E). Vehicle treated Rag1-/- mice show higher 
APP-positive axonal spheroids (arrowhead) in the corpus callosum (F) than the LAQ-treated group 
(G). Vehicle group displays more extensive fiber gliosis in the corpus callosum (H) than LAQ-treated 
mice (I). Representative images of the medial part of the corpus callosum were taken at 400x original 
magnification (scale bars: 50 µm).  
Fig. 8: No cuprizone-induced 
weight loss in LAQ-treated Rag1-/- 
mice. Body weights of vehicle- and 
LAQ-treated Rag1-/- animals after 6 
weeks of 0.25% cuprizone. LAQ-
treated Rag1-/- mice show 
significantly higher body weights 
after cuprizone compared to 
vehicle-treated animals (*p < 0.05). 
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Many activated microglia were detected in the corpus callosum of vehicle-treated 
Rag1-/- mice (Fig. 9D) whereas only scattered microglia were observed under LAQ treatment 
(Fig. 9E). Numerous APP-positive axonal spheroids were detected in the vehicle group      
(Fig. 9F), but LAQ-treated Rag1-/- animals showed fewer axonal damage in the corpus 
callosum (Fig. 9G). In addition, GFAP staining revealed that Rag1-/- mice treated with vehicle 
displayed more extensive fiber gliosis in the corpus callosum (Fig. 9H) than LAQ-treated 
Rag1-/- animals (Fig. 9I). 
 
3.1.6 Decreased astrocytic NF-κB activation under LAQ treatment after 
cuprizone 
The data presented above provide evidence that LAQ protects from cuprizone-
induced pathology through CNS-intrinsic mechanisms. Similar protective effects as observed 
in the present cuprizone experiments have been observed in mice in which the NF-κB 
pathway was selectively inhibited in astrocytes (Raasch et al., 2011). Hence, the effects of 
LAQ on NF-κB activation in astrocytes were analyzed in detail. Therefore, astrocytic p65 




Fig. 10: LAQ reduces astrocytic NF-κB activation after 6 weeks of cuprizone challenge. Double 
immunohistochemistry with antibodies against p65 (red) and GFAP (green) shows significantly fewer 
GFAP-positive astrocytes with nuclear p65 immunoreactivity in the corpus callosum in LAQ-treated 
(14% ± 1%) (B) in comparison to vehicle-treated mice (26% ± 1%, ***p < 0.001) (A, C). Representative 
images of the corpus callosum were taken at 400x original magnification (scale bars: 20 µm).  
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Double immunofluorescence staining against antibodies of p65 and GFAP were 
performed to detect nuclear translocation of p65/RelA, the main transactivating NF-κB 
subunit, in astrocytes. Compared to vehicle-treated mice (Fig. 10A) fewer p65-positive 
astrocytes were detected in the corpus callosum of LAQ-treated animals (Fig. 10B). 
Quantitative analysis revealed that the proportion of astrocytes with nuclear p65 
immunoreactivity was significantly lower in the LAQ group (14% ± 1% GFAP-positive 
astrocytes with nuclear translocation of p65) compared to the vehicle group (26% ± 1%;        
p < 0.001) (Fig. 10C).  
 
3.1.7 No LAQ effect on LPC-induced demyelination 
To assess the effect of preventive treatment with 25 mg/kg LAQ in a model with focal 
rapid demyelination, 1 µl 1% LPC was injected stereotactically in the corpus callosum. 
Vehicle-treated controls and LAQ-treated animals were evaluated histologically. Four days 
after LPC injection, demyelination was examined in the corpus callosum of both groups.  
 
 
Fig. 11: No effect of 25 mg/kg LAQ on LPC-induced demyelination. Similar extent of demyelination 
in vehicle-treated mice (A) and animals treated with 25 mg/kg LAQ (B) on LFB-PAS-stained sections of 
the corpus callosum 4 days after focal injection. Evaluation of the lesion area revealed no significant 
difference between both treatment groups (p > 0.05) (C). The Bielschowsky staining of the LPC-
induced lesion displayed intact axons in vehicle- (D) and LAQ-treated (E) mice. Representative images 
of the lesion site were taken at 100x original magnification (scale bars: 200 µm).  
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Vehicle- and LAQ-treated mice displayed focal demyelination in the corpus callosum 
(Fig. 11A, B). Evaluation of the lesion area revealed a similar extent of demyelination in both 
groups (vehicle: 120,539 ± 35,482 µm2; LAQ: 124,400 ± 50,648 µm2; p > 0.05) (Fig. 11C). 
There was only little axonal damage in both groups after LPC injection (Fig. 11D, E). 
Further experiments were performed with a higher LAQ concentration of 40 mg/kg. 
In these experiments, vehicle- (Fig. 12A) and LAQ-treated animals (Fig. 12B) displayed focal 
demyelination of the corpus callosum. However, evaluation of the lesion area demonstrated 
a similar extent of demyelination after four days of LAQ treatment (vehicle: 107,821 ± 
38,802 µm2; LAQ: 94,561 ± 42,071 µm2; p > 0.05) (Fig. 12C). Only minimal axonal damage 
was observed in vehicle-treated mice (Fig. 12D) and animals treated with the higher LAQ 
concentration (Fig. 12E).  
 
 
Fig. 12: No effect of 40 mg/kg LAQ on LPC-induced demyelination. Similar callosal demyelination in 
vehicle-treated animals (A) and mice treated with 40 mg/kg LAQ (B) on LFB-PAS stained sections        
4 days after stereotactical injection. Evaluation of the lesion area of the corpus callosum 
demonstrates no significant difference between vehicle and LAQ group (p > 0.05) (C). The 
Bielschowsky staining of the LPC-induced lesion area displays intact axons in vehicle (D) and LAQ-
treated (E) mice. Representative images of the lesion site were taken at 100x original magnification 
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3.1.8 Similar remyelination under LAQ after cuprizone withdrawal 
 To investigate the effect of LAQ on remyelination and oligodendrocyte repopulation, 
mice received a 0.25% cuprizone diet for six weeks without LAQ treatment to induce 
demyelination. After cuprizone withdrawal, mice were treated with vehicle or 25 mg/kg LAQ 
during the remyelinating period of four days. Both groups were evaluated histologically. 
After four days of remyelination, vehicle- (Fig. 13A) and LAQ-treated mice (Fig. 13B) 
displayed extensive remyelination which was evidenced by immunohistological staining 




Fig. 13: No effect of LAQ on remyelination after cuprizone-induced demyelination. Vehicle-treated 
animals (A) and mice treated with 25 mg/kg LAQ (B) show extensive remyelination 4 days after 
withdrawal from 6 weeks 0.25% cuprizone challenge. Density of NogoA-positive oligodendrocytes 
(arrowheads) is similar in both treatment groups (C, D). Quantification of mature oligodendrocytes 
reveals no significant difference between vehicle- and LAQ-treated animals (E) (p > 0.05). 
Representative images of the corpus callosum were taken at 100x (A, B) or 400x (C, D) original 
magnification (scale bars: 200 µm (A, B) and 50 µm (C, D). Inserts show magnified representative 
cells.  
 
To determine oligodendroglial repopulation, the density of callosal NogoA-positive 
oligodendroglial cells was quantified. Vehicle- (Fig. 13C) and LAQ-treated mice (Fig. 13D) 
showed numerous oligodendrocytes in the corpus callosum after four days of remyelination. 
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The densities of mature oligodendrocytes were similar in both groups (vehicle: 496 ± 152 
NogoA-positive cells per mm2; LAQ: 580 ± 125 NogoA-positive cells per mm2; p > 0.05)      
(Fig. 13E). In conclusion, LAQ did not affect remyelination and oligodendroglial repopulation 
after cuprizone challenge.  
 
3.2 Investigating the impact of human GFAP overexpression on 
toxic demyelination in mice  
3.2.1 Increased astrogliosis, but regular myelin and oligodendroglial density 
in naïve Tg(hGFAP) mice 
 Before evaluation of potential cuprizone-induced effects on Tg(hGFAP) mice, naïve 
animals of this transgenic line were characterized. Previous studies indicate that these 
animals overexpressing human GFAP show an increased astrogliosis without external stimuli 
(Messing et al., 1998). In eight-weeks-old naïve wild type mice, the cortex showed nearly no 
GFAP-positive astrocytes (Fig. 14A) whereas age-matched naïve Tg(hGFAP) animals showed 
many islets of GFAP-positive astrocytes (Fig. 14B). At the age of 14 weeks, a time point 
comparable with six weeks of cuprizone feeding, naïve transgenic mice showed extensive 
GFAP-positive astrocytes in the cortex (Fig. 14C). At the age of eight weeks, the subpial 
cortex of naïve wild type animals showed only scattered GFAP-positive astrocytes (Fig. 14D) 
whereas the subpial cortex of age-matched transgenic mice showed increased GFAP-positive 
astrocytes with thickened astrocytic branches and magnified nuclei (Fig. 14E). Even more 
GFAP-positive astrocytes with magnified nuclei and astrogliosis were observed at 14 weeks 
of age (Fig. 14F). Compared to eight-weeks-old wild type animals (Fig. 14G) the corpus 
callosum of Tg(hGFAP) mice showed increased GFAP-positive astrocytes with abnormal 
appearing branches (Fig. 14H). At the age of 14 weeks, the corpus callosum of transgenic 
animals showed even more GFAP-positive astrocytes and thickened astrocytic branches   
(Fig. 14I). 
 




Fig. 14: Increased astrogliosis in naïve Tg(hGFAP) mice. Compared to wild type animals (A, D, G) 
mice overexpressing human GFAP (B-C, E-F, H-I) show increased GFAP-positive astrocytes in the 
cortex (A-C), subpial cortex (D-F) and corpus callosum (G-I) at the age of 8 weeks (A-B, D-E, G-H) and 
14 weeks (C, F, I). Representative images were taken at 40x (A-C) and 400x original magnification   
(D-I) (scale bars: 500 µm and 50 µm).  
 
The myelin content, the presence of activated microglia and number of mature 
oligodendrocytes were investigated in naïve animals. Eight-weeks-old naïve wild type mice 
showed a regular myelin content of the corpus callosum (Fig. 15A) which appeared similar in 
age-matched Tg(hGFAP) animals (Fig. 15B). Only few activated microglia were detected in 
the corpus callosum of naïve wild type mice (Fig. 15C). Animals overexpressing human GFAP 
demonstrate scattered activated microglia (Fig. 15D) and their density appeared similar to 
wild type mice. 




Fig. 15: Regular myelin content, activated microglia and number of mature oligodendrocytes in 
Tg(hGFAP) mice at the age of 8 weeks. Compared to naïve wild type mice (A, C, E) age-matched 
naïve Tg(hGFAP) mice (B, D, F) show similar myelin content of the corpus callosum on LFB-PAS-
stained sections (A-B). Mac3-staining reveals similar densities of activated microglia (arrowheads) in 
the corpus callosum of wild type (C) and transgenic animals (D). Similar densities for NogoA-positive 
oligodendrocytes (arrowheads) are detected in the corpus callosum of wild type (E) and transgenic 
mice (F). Quantification of mature oligodendrocytes confirmed no significant difference in the 
number of oligodendrocytes between both groups (G) (p > 0.05). Representative images were taken 
at 40x (A-B) and 400x original magnification (C-F) (scale bars: 500 µm and 50 µm). Inserts show 
magnified representative cells.  
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Many mature oligodendrocytes were obvious in the corpus callosum of eight-weeks-
old wild type (Fig. 15E) and transgenic mice (Fig. 15F). Quantification of NogoA-positive 
oligodendrocytes revealed similar numbers of mature oligodendrocytes in both groups (wild 
type: 996 ± 95 NogoA-positive cells per mm2; Tg(hGFAP): 943 ± 149 NogoA-positive cells per 
mm2; p > 0.05) (Fig. 15G). 
 
3.2.2 Reduced cuprizone-induced oligodendroglial apoptosis in Tg(hGFAP) 
mice 
The effect of an increased astrogliosis on cuprizone-induced demyelination was 
evaluated clinically and histologically in wild type and Tg(hGFAP) mice. Both groups showed 
an initial weight loss during the first week of cuprizone challenge. During six weeks of 
cuprizone treatment, transgenic mice showed significantly relative less weight loss than wild 
type mice after four, five and six weeks of cuprizone (Fig. 16).  
 
 
Fig. 16: Reduced weight loss in Tg(hGFAP) mice after cuprizone. Body weights of wild type and 
transgenic mice at weeks 0-6 during 0.25% cuprizone challenge. Transgenic mice show significantly 
higher body weights than wild type animals after 4, 5 and 6 weeks of cuprizone (**p < 0.01;              
*p < 0.05).  
 
After one week of cuprizone, wild type animals showed numerous HE-stained 
apoptotic cells in the corpus callosum (Fig. 17A) whereas Tg(hGFAP) mice displayed only 
scattered apoptotic cells (Fig. 17B). Quantitative analysis revealed that the density of 
apoptotic cells was significantly reduced in transgenic animals after one week of cuprizone 
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(28 ± 19 apoptoses per mm2) in comparison to wild type mice (102 ± 35 apoptoses per mm2; 
p < 0.001) (Fig. 17C).  
 
 
Fig. 17: Decreased oligodendroglial apoptosis in Tg(hGFAP) mice. Wild type animals (A) show 
significantly more apoptotic cells (arrowheads) in the corpus callosum than mice overexpressing 
human GFAP (B, C) after 1 week of 0.25% cuprizone (***p < 0.001). Compared to wild type mice (D) 
caspase3-positive apoptotic cells (arrowheads) are significantly decreased in transgenic animals (E, 
F). NogoA-positive oligodendrocytes (arrowheads) are significantly lower in wild type (G) compared 
to transgenic animals (**p < 0.01) (H, I). Oligodendrocytes are positive for CNPase (red arrowhead) 
(J). Some of the apoptotic cells are CNPase-positive (black arrowhead) indicating that these apoptotic 
cells are oligodendrocytes. Representative images of the medial part of the corpus callosum were 
taken at 400x original magnification (scale bars: 50 µm) (B-I) or at 1,000x original magnification (scale 
bar: 10 µm) (K). Inserts show magnified representative cells.  
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Caspase3-positive apoptoses were also reduced in transgenic (Fig. 17E) compared to 
wild type animals (Fig. 17D). The density of callosal caspase3-positive apoptotic cells was 
significantly reduced in human GFAP overexpressing than in wild type mice (19 ± 15 vs. 93 ± 
21 caspase3-positive apoptoses per mm2; p < 0.01) (Fig. 17F).  
To determine whether an increased astrogliosis exerts effects on mature 
oligodendrocytes, numbers of NogoA-positive oligodendrocytes were assessed. NogoA-
positive mature oligodendrocytes were detected in the callosal white matter in both groups. 
The number of oligodendrocytes was reduced in wild type mice (Fig. 17G) whereas 
Tg(hGFAP) animals showed numerous NogoA-positive oligodendrocytes (Fig. 17H). 
Quantitative evaluation revealed that the density of mature oligodendrocytes was 
significantly higher in human GFAP overexpressing (900 ± 193 NogoA-positive cells per mm2) 
compared to wild type animals (650 ± 72 NogoA-positive cells per mm2; p < 0.01) (Fig. 17I). 
Few apoptotic cells were immunopositive for CNPase identifying these apoptotic cells as 
oligodendrocytes (Fig. 17J). 
 
3.2.3 Less cuprizone-induced demyelination in Tg(hGFAP) animals  
To test whether an increased astrogliosis affects cuprizone-induced demyelination, 
Tg(hGFAP) mice and wild type littermates received 0.25% cuprizone for six weeks. 
Demyelination was evaluated in the corpus callosum of both groups.  
 
 
Fig. 18: Less callosal demyelination in Tg(hGFAP) mice. 
Compared to wild type animals showing extensive 
demyelination of the corpus callosum (A, C) the myelin of 
transgenic mice appeared mainly intact (B, D) after 6 weeks of 
0.25% cuprizone on LFB-PAS-stained sections. Semi 
quantitative scores for demyelination are significantly higher in 
wild type than in transgenic mice (***p < 0.001) (E). Scale bars: 
A-B 500 µm, C-D 50 µm. 
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Wild type animals displayed widespread callosal demyelination (Fig. 18A, C) whereas 
the myelin appeared mainly intact in the corpus callosum of transgenic mice (Fig. 18B, D). 
Demyelination scores were significantly higher in wild type mice (score 2.9 ± 0.3) compared 
to transgenic animals (score 0.4 ± 0.5; p < 0.001) (Fig. 18E).  
 
3.2.4 Less microglial activation and axonal damage in Tg(hGFAP) mice after 
cuprizone challenge 
To detect further effects of an increased astrogliosis on cuprizone-induced pathology, 
microglial activation and axonal damage were evaluated in wild type and human GFAP 
transgenic animals. Mac3 staining revealed fewer activated microglial cells in the corpus 
callosum of transgenic animals (Fig. 19B) in comparison to wild type mice (Fig. 19A).           
The microglia density within the corpus callosum was significantly reduced in Tg(hGFAP)  
(171 ± 106 Mac3-positive cells per mm2) compared to wild type animals (684 ± 330 Mac3-
positive cells per mm2; p < 0.001) (Fig. 19C).  
 
 
Fig. 19: Reduced cuprizone-induced microglial activation and axonal damage in human GFAP 
transgenic mice. Transgenic animals display less microglial activation (A-C) and axonal damage (D-F) 
compared to wild type mice after 6 weeks of 0.25% cuprizone. The density of Mac3-positive microglia 
(arrowheads) is significantly higher in wild type (A) compared to human GFAP transgenic mice (B, C) 
(***p < 0.001). Inserts show magnified representative cells. Compared to wild type mice (D) APP-
positive axonal spheroids (arrowheads) are significantly reduced in Tg(hGFAP) animals (E, F)        
(***p < 0.001). Representative images of the medial part of the corpus callosum were taken at 400x 
original magnification (scale bars: 50 µm).  
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Wild type animals showed numerous damaged axons (Fig. 19D) whereas nearly no 
APP-positive axons were detected in transgenic mice (Fig. 19E). The quantitative analysis 
revealed a significant reduction of acute axonal damage in human GFAP transgenic 
compared to wild type mice (5 ± 4 vs. 179 ± 38 APP-positive axons per mm2, p < 0.001)     
(Fig. 19F). 
 
3.2.5 Similar cerebral cuprizone concentrations in Tg(hGFAP) and wild type 
mice 
To assess whether cuprizone levels were comparable in human GFAP overexpressing 
and wild type animals, cuprizone concentrations were measured in brain tissue of both 
groups after one week (Fig. 20A) and six weeks (Fig. 20B) of cuprizone feeding. The cerebral 
cuprizone concentrations did not differ significantly between wild type and transgenic mice 
after one week (wild type: 108 ± 74 ng/g brain tissue, Tg(hGFAP): 230 ± 175 ng/g brain 
tissue) (Fig. 20A) and after six weeks of cuprizone (wild type: 143 ± 69 ng/g brain tissue, 
Tg(hGFAP): 228 ± 128 ng/g brain tissue) (Fig. 20B).  
 
 
Fig. 20: Similar cuprizone concentration in brains of human GFAP transgenic and wild type mice. 
After 1 week (A) and 6 weeks (B) of 0.25% cuprizone treatment, cuprizone was quantified in brain 
samples of Tg(hGFAP) and wild type animals by RP-HPLC mass spectrometry analysis. Cuprizone 
concentrations are similar for both treatment regimes after both time spans (p > 0.05).  
 
To determine whether cuprizone levels in plasma were comparable in both groups, 
mass spectrometry analyses were performed after one week (Fig. 21). Cuprizone 
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concentrations in plasma were very low and similar in both groups. They did not show any 
significant differences between wild type and human GFAP overexpressing animals (wild 




3.2.6 Reduced astrocytic NF-κB activation in Tg(hGFAP) mice after cuprizone 
To investigate whether the overexpression of human GFAP exerts effects on NF-κB 
activation in astrocytes, nuclear translocation of p65/RelA in astrocytes was detected by 
double immunofluorescence staining against antibodies of p65 and GFAP after six weeks of 
cuprizone. The proportion of astrocytes with nuclear p65 immunoreactivity was significantly 




Fig. 22: Reduction of astrocytic NF-κB activation in 
Tg(hGFAP) mice. Proportion of callosal astrocytes with 
nuclear p65 immunoreactivity is significantly reduced in 
Tg(hGFAP) animals (5% ± 1%) in comparison to vehicle-
treated mice (25% ± 3%, **p < 0.01) after 6 weeks of 0.25% 
cuprizone which was indicated by double 
immunohistochemistry with antibodies against p65 and 
GFAP. 
 
Fig. 21: Low cuprizone concentration in plasma of 
human GFAP transgenic and wild type mice. After         
1 week of 0.25% cuprizone treatment, cuprizone was 
quantified in plasma samples of Tg(hGFAP) and wild 
type animals by RP-HPLC mass spectrometry analysis. 
Cuprizone concentrations are similar for both treatment 
regimes (p > 0.05).  
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3.3 Examining the short-term effects of cuprizone in vitro and       
in vivo  
3.3.1 No effect of cuprizone on astrocytic viability, but on astrocytic 
migration in vitro 
To examine whether cuprizone directly affects astrocytic viability in vitro, primary 
mouse astrocytes were treated with 1 µM, 10 µM or 100 µM cuprizone for 24 h. Untreated 
astrocytes served as controls. Mitochondrial respiration assessed by MTT assays was not 
affected by the treatment with 1 µM (102% ± 4% respiration capacity), 10 µM (100% ± 7% 
respiration capacity) or 100 µM cuprizone (92% ± 11% respiration capacity) compared to 
untreated control astrocytes (100% ± 3% respiration capacity; p > 0.05) (Fig. 23A).              
The amount of astrocytic cell damage measured by lactate dehydrogenase assays (CytoTox 
One-Assay) was not significantly increased after treatment with 1 µM (11,637 RFU ± 1,620 
RFU), 10 µM (11,541 RFU ± 3,970 RFU) or 100 µM cuprizone (11,624 RFU ± 3,213 RFU) 




Fig. 23: No effect of cuprizone on primary astrocytes 
from wild type mice. Treatment with 1 µM, 10 µM or 
100 µM cuprizone for 24 h shows no effect on 
mitochondrial respiration assessed by MTT assays (A) 
and cell damage measured by lactate dehydrogenase 
(cytotoxicity) assays (B) in astrocytes. Untreated cells 
served as controls. B: RFU = relative fluorescence 
units.  
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To test whether cuprizone treatment affects the ability of astrocytes to migrate in a 
cell-free area, a scratch was made in a cell monolayer and astrocytes were treated with 
different cuprizone concentrations for up to 42 h. Primary astrocytes were treated with        
1 µM cuprizone (Fig. 24B, F, J), 10 µM (Fig. 24C, G, K) or 100 µM cuprizone (Fig. 24D, H, L). 
Untreated astrocytes served as controls (Fig. 24A, E, I). At the beginning of the experiment, 
the size of the cell-free area was similar in all treatment conditions (Fig. 24A-D). After 24 h, 
astrocytes migrated into the cell-free area which has become smaller (Fig. 24E-H). After 42 h, 
the scratch was almost completely closed after treatment with 0 and 1 µM cuprizone       
(Fig. 24I, J), but the gap was still visible after treatment with the higher cuprizone doses of  
10 and 100 µM (Fig. 24 K, L). Hence, treatment with high cuprizone doses showed no effect 
on astrocytic survival, but led to mild inhibition of astrocytic migration. 
 
 
Fig. 24: Mildly reduced astrocytic migration under high cuprizone doses. A scratch is made in a cell 
monolayer at the beginning (0 h, A-D) and the ability to migrate is compared after 24 h (E-H) and     
42 h (I-L). Treatment with the higher cuprizone doses of 10 µM (C, G, K) and 100 µM cuprizone (D, H, 
L) show a mild inhibition of astrocytic migration in comparison to astrocytes treated with 0 (A, E, I) or 
1 µM cuprizone (B, F, J) (scale bars: 5 µm).  
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3.3.2 No effect of serum from cuprizone-treated mice on astrocytic viability 
and migration in vitro 
To assess whether a metabolite of cuprizone might exert direct effects on astrocytes 
in vitro, primary mouse astrocytes were treated with medium containing 10% serum from 
cuprizone-treated mice or 10% serum from naïve mice as control for 24 h. Untreated 
astrocytes served as controls. Astrocytes treated with medium containing 10% serum from 
cuprizone-treated mice showed similar mitochondrial respiration (113% ± 19% respiration 
capacity) as control astrocytes (100% ± 0% respiration capacity) which was assessed by MTT 
assays (Fig. 25). Furthermore, astrocytes treated with 10% serum from cuprizone-treated 
animals demonstrated similar mitochondrial respiration as astrocytes treated with medium 
containing 10% serum from naïve animals (109% ± 4%; p > 0.05) (Fig. 25). The effect of 
serum on astrocytic cell damage was not evaluated by lactate dehydrogenase assays 
(CytoTox One Assay) since serum itself interfered with fluorescence measurements.  
 
 
Fig. 25: No effect of serum from cuprizone-treated mice on mitochondrial respiration in primary 
astrocytes from wild type animals. No effect of serum from cuprizone-treated mice on astrocytes 
assessed by MTT assays (p > 0.05). Primary astrocytes were treated with medium containing 10% 
serum from naïve mice or 10% serum from cuprizone-treated animals for 24 h. Untreated cells 
served as controls.  
 
To determine whether the serum from cuprizone-treated mice affects astrocytic 
migration, a scratch was made in a cell monolayer and astrocytes were treated with medium 
containing 10% serum from cuprizone-treated mice (Fig. 26C, F, I) or 10% serum from naïve 
animals (Fig. 26B, E, H) for 42 h. Untreated astrocytes only incubated with medium without 
any serum served as controls (Fig. 26A, D, G). At the beginning of the experiment the cell-
free area was made by scratching the cells (Fig. 26A-C). After 24 h the cell-free area became 
smaller due to astrocytic migration (Fig. 26D-F). After 42 h the scratch was almost 
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completely closed by astrocytes. Compared to untreated astrocytes (Fig. 26G) no marked 
difference between astrocytes treated with serum from naïve mice (Fig. 26H) or serum from 
cuprizone-treated animals (Fig. 26I) was observed after 42 h. Hence, treatment with serum 
from cuprizone-treated mice showed no effect on mitochondrial respiration of astrocytes or 
astrocytic migration.  
 
 
Fig. 26: No effect of serum from cuprizone-treated mice on migration of primary mouse astrocytes. 
A scratch is made in a cell monolayer at the beginning (0 h, A-C) and the ability to migrate is 
compared after 24 (D-F) and 42 h (G-I). Treatment with serum from naïve mice (B, E, H) or serum 
from cuprizone-treated mice (C, F, I) shows no effect on migration compared to untreated astrocytes 
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3.3.3 No direct cuprizone effect on glial cells after intracerebral injection       
in vivo 
To examine whether stereotactical injection of cuprizone might cause demyelination 
or oligodendroglial apoptosis, mice were focally injected with 200 µM cupizone or PBS as 
control. The lesion site was identified by the blue dye included in the injection solution. Four 
days after injection, no demyelination was observed in mice injected with PBS (Fig. 27A) or 
cuprizone (Fig. 27B) and the myelin appeared intact. Evaluation of GFAP-stained sections 
revealed no loss of astrocytes at the lesion site or in adjacent tissue after focal injection of 
PBS (Fig. 27C) or 200 µM cuprizone (Fig. 27D). Staining against NogoA demonstrated no loss 
of mature oligodendrocytes in both groups (Fig. 27E, F). Only few scattered apoptotic cells 
were observed after stereotactical injection of cuprizone or PBS (data not shown). Hence, 
focal injection of cuprizone did not affect myelin content or the presence of astrocytes and 
oligodendrocytes. 
 
3.3.4 No direct effect of serum from cuprizone-treated mice after 
intracerebral injection in vivo  
Focal injection of cuprizone did not cause demyelination or loss of oligodendrocytes 
and astrocytes raising the question whether a metabolite of cuprizone leads to cuprizone-
induced pathology in vivo. Therefore, serum from cuprizone-treated mice was injected in the 
corpus callosum of wild type animals. Control mice were injected with serum from naïve 
animals. Four days after injection, similar myelin content was observed in mice injected with 
naïve serum (Fig. 28A) or serum from cuprizone-treated animals (Fig. 28B). Around the 
injection site GFAP-positive astrocytes were present in both groups (Fig. 28C, D). Mature 
oligodendrocytes appeared to be unaffected by focal injection of naïve serum (Fig. 28E) or 
serum from cuprizone-treated mice (Fig. 28F). Only few apoptosis were observed after 
stereotactical injection of cuprizone or control serum and the density of apoptotic cells were 
similar in both groups (data not shown). Hence, focal injection of serum from cuprizone-
treated mice did not cause demyelination or loss of oligodendrocytes and astrocytes. 





Fig. 27: No effect of cuprizone after focal injection in wild type mice. The lesion site was identified 
by the blue dye. Similar myelin content (A-B), presence of astrocytes (C-D) and mature 
oligodendrocytes (E-F) 4 days after stereotactical injection of PBS (A, C, E) and 200 µM cuprizone    
(B, D, F). MBP-stained sections show no demyelination after focal injection of PBS (A) or cuprizone 
(B). GFAP-positive astrocytes are present after focal injection of PBS (C) and cuprizone (D). NogoA-
positive oligodendrocytes are present in the injection site and in adjacent tissue in PBS- (E) and 
cuprizone-injected mice (F). Representative images of the lesion site were taken at 100x original 








Fig. 28: No effect of serum from cuprizone-treated mice after focal injection in wild type animals. 
The lesion site was identified by the blue dye. Similar myelin content (A-B), presence of astrocytes  
(C-D) and mature oligodendrocytes (E-F) in mice 4 days after focal injection of serum from cuprizone-
treated animals (B, D, F) and naïve serum (A, C, E). No demyelination was detected on MBP-stained 
sections after stereotactical injection of control serum (A) or cuprizone serum (B). GFAP-stained 
astrocytes are present in the injection site and in adjacent tissue after focal injection of cuprizone 
serum (D) compared to naïve serum (C). NogoA staining reveals no loss of oligodendrocytes after 
injection of naïve serum (E) and serum from cuprizone-treated mice (F). Representative images of 
the lesion site were taken at 100x original magnification (scale bars: 200 µm). Inserts show magnified 
representative cells. 
 





The present study investigated intrinsic and therapy-induced astrocytic effects on 
cuprizone-induced pathology in mice.  
The first aim of this work was to study the effects of LAQ on toxin-induced changes. 
In the cuprizone model, LAQ prevented demyelination, microglial activation, axonal damage, 
reactive astrogliosis and oligodendroglial apoptosis. Astrocytic NF-κB activation was 
significantly decreased by 46% under 25 mg/kg LAQ compared to the vehicle group after six 
weeks of cuprizone. These data indicate that LAQ might protect from cuprizone-induced 
pathology through CNS-intrinsic mechanisms by reducing NF-κB activation in astrocytes.    
This effect of LAQ was independent of T and B cells as evidenced by similar findings in Rag1-
deficient mice. However, LAQ did not affect remyelination after cuprizone challenge or LPC-
induced demyelination.  
The second aim of this work was to study the impact of increased astrocytic GFAP 
expression on cuprizone-induced changes. Transgenic mice overexpressing human GFAP 
showed less demyelination, microglial activation and axonal damage. Oligodendroglial 
apoptosis and loss of oligodendrocytes were reduced after short cuprizone challenge. After 
six weeks of cuprizone transgenic mice displayed an 80% reduction of astrocytic NF-κB 
activation compared to wild type mice. 
A third minor aim of the present work was to examine direct effects of cuprizone on 
astrocytes in vitro and in vivo. In vitro, neither cuprizone nor serum from cuprizone-treated 
mice did affect mitochondrial respiration, astrocytic cell damage or migration capacity in 
primary mouse astrocytes. In vivo, myelin content and glial cells were not affected by focal 
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4.1 Reduced cuprizone-induced pathology under LAQ by down-
regulation of astrocytic NF-κB activation  
4.1.1 Reduced cuprizone-induced weight loss and oligodendroglial apoptosis 
under LAQ 
After one week of cuprizone challenge, there was no cuprizone-induced weight loss 
under LAQ treatment. At this time point, body weights in the vehicle group were reduced by 
11% compared to initial weights whereas body weights in the LAQ group were not affected. 
During the further course of cuprizone challenge LAQ-treated mice displayed significantly 
higher body weights compared to vehicle-treated animals. Oligodendroglial apoptosis was 
reduced by 62% in LAQ-treated mice compared to vehicle-treated controls after one week of 
cuprizone.  
To date, the exact mechanisms leading to cuprizone-induced weight loss as well as 
oligodendroglial apoptosis are not known. Both weight loss and oligodendroglial cell death 
under cuprizone are early changes that can be observed within the first week of cuprizone 
exposure (Hesse et al., 2010). It is possible that cuprizone-induced oligodendroglial 
dysfunction and apoptosis might lead to slight cerebral dysfunction resulting in reduced 
general condition paralleled by a loss of appetite during the first and perhaps the following 
week(s) of cuprizone exposure.  
 
4.1.2 Dose-dependent inhibition of demyelination under LAQ 
After six weeks of cuprizone, LAQ-treated animals showed preservation of myelin in a 
dose-dependent manner. Vehicle-treated controls showed almost complete demyelination 
whereas mice treated with 5 mg/kg LAQ showed moderate demyelination compared to 
mainly intact myelin in animals treated with 25 mg/kg LAQ as shown by histological 
examination. These data demonstrate significantly reduced cuprizone-induced 
demyelination in the LAQ-treated group. 
The concentration of 25 mg/kg LAQ was chosen for experiments since this 
concentration was well-tolerated and showed good efficacy in previous EAE studies 
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(Runström et al., 2006). The lower concentration of 5 mg/kg LAQ was also shown to 
attenuate EAE severity in SJL/N animals (Brunmark et al., 2002).  
In clinical trials the administered LAQ concentration in humans is 0.6 mg per day 
since this dose was well-tolerated and showed clinical effects on relapses and disability 
(Comi et al., 2012). The different dosages between mice and man are partly explained by a 
longer half-life in humans (approximately 70 hours) compared to mice (approximately three 
to seven hours) (Brück and Wegner, 2011). 
 
4.1.3 Less microglial activation, axonal damage and astrogliosis under LAQ 
After six weeks of cuprizone, LAQ-treated mice demonstrated significantly less 
microglial activation, axonal damage and astrogliosis within the CNS. Density of activated 
microglia was reduced by 82% in LAQ-treated compared to vehicle-treated animals. Acute 
axonal damage, measured as APP-positive axonal spheroids, was reduced by 97% under LAQ 
treatment compared to the vehicle group. Reactive astrogliosis was also inhibited in LAQ-
treated compared to vehicle-treated mice after six weeks of cuprizone. 
Activation of CNS-resident microglia appeared to be the most important component 
for cuprizone-induced demyelination whereas macrophages and T cells only have a minor 
contribution to cuprizone-induced pathology (Remington et al., 2007). T cells recruited to 
the demyelinated tissue did not appear activated and infiltration of macrophages was 
negligible (Remington et al., 2007). 
Demyelination is associated with axonal damage and astrogliosis in the CNS. This 
acute axonal damage leads to irreversible axonal loss. This axonal damage was almost 
absent in LAQ-treated compared to vehicle-treated mice. This reduced tissue damage in the 
LAQ group is probably due to reduced cuprizone-induced demyelination under LAQ. 
Previously, LAQ was shown to exert similar beneficial effects on inflammation and axonal 
pathology in mice with EAE (Wegner et al., 2010).  
In demyelinated tissue GFAP protein expression in astrocytes is elevated as response 
to tissue damage. This increase of GFAP is a major feature of complex astrocytic changes 
referred to as reactive astrogliosis (Roessmann and Gambetti, 1986).  
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4.1.4 Similar cerebral cuprizone concentrations in LAQ- and vehicle-treated 
mice 
Mass spectrometry analyses demonstrated no significant difference between 
cerebral cuprizone concentrations of LAQ- and vehicle-treated mice neither after one week 
nor after six weeks of cuprizone challenge. Cuprizone concentrations in plasma did not show 
any significant difference between both groups after one week of cuprizone either. These 
data suggest that the observed differences in demyelination, microglial activation, axonal 
damage and astrogliosis between both groups cannot be explained by different cuprizone 
concentrations in brain and plasma.  
Previous studies also demonstrated the presence of cuprizone in brain and plasma 
samples after six months of cuprizone challenge which was assessed by mass spectrometry 
analyses (Zatta et al., 2005). Further explanations for the observed differences in 
demyelination, microglial activation, axonal damage and astrogliosis between LAQ and 
vehicle groups might the existence of cuprizone-related metabolites which could also be 
responsible for cuprizone-induced effects. However, the existence of potential cuprizone 
metabolites is not known (Zatta et al., 2005) and hence could not be measured in the 
present thesis. 
 
4.1.5 LAQ-related changes independent of T and B cells 
Similar to wild type mice, LAQ-treated Rag1-/- animals lacking T and B cells 
demonstrated reduced cuprizone-induced pathology after six weeks of cuprizone. Treated 
mice displayed reduced cuprizone-induced weight loss, demyelination, microglial activation, 
axonal damage and astrogliosis. These results indicate that the effect of LAQ in the cuprizone 
model is independent of T and B cells. Indeed, cuprizone-induced demyelination takes place 
in the near absence of T cells with an intact BBB as evidenced by previous studies indicating 
similar findings in Rag1-/- and wild type mice after cuprizone challenge (Matsushima and 
Morell, 2001; Hiremath et al., 2008). In healthy mice, studies using whole-body 
autoradiography demonstrate that 7 to 8% of LAQ penetrates through the intact BBB and 
reaches the brain in relation to the blood concentration (Brück and Wegner, 2011). Taken 
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together, these findings in Rag1-/- and wild type mice suggest that LAQ has direct protective 
effects on the CNS. 
 
4.1.6 Reduced astrocytic NF-κB activation by LAQ 
The significant inhibition of reactive astrogliosis in the present study, as well as the 
observation that astrocytic NF-κB activation is necessary for cuprizone-induced 
demyelination (Raasch et al., 2011), led to more detailed examinations of the role of 
astrocytic NF-κB activation. The reduced reactive astrogliosis seen in LAQ-treated animals 
was paralleled by a 46% reduction of astrocytic NF-κB activation in LAQ-treated mice in vivo 
after six weeks of cuprizone. In addition, microglial NF-κB activation did not differ between 
LAQ- and vehicle-treated animals after six weeks of cuprizone (oral communication by Dr. N. 
Kramann, Dept. of Neuropathology, University Medical Center Göttingen, Germany). 
Further evidence comes from in vitro studies demonstrating that astrocytic, but not 
microglial, NF-κB activation was also reduced by LAQ by 46% in primary mouse cells assessed 
by NF-κB reporter assays (Brück et al., 2012). The inhibition of astrocytic NF-κB activation    
in vitro was already observed after one hour. In addition, this publication also showed that 
LAQ-treated primary astrocytes displayed a down-regulation of various astrocytic              
pro-inflammatory markers (Brück et al., 2012). In vivo and in vitro data demonstrating 
reduced astrocytic, but similar microglial, NF-κB activation under LAQ suggesting that LAQ 
affects upstream pathways causing NF-κB activation differentially in astrocytes and 
microglia.  
In the CNS, astroglial NF-κB activation has a dual role and can cause both deleterious 
and beneficial effects. Beneficial effects include ischemia-related changes of glutamate 
transport in mice constitutively deficient for GFAP and Vimentin (Li L. et al., 2008) and 
increased neurotrophic factors in primary rat astrocytic cultures (Zaheer et al., 2001). 
Deleterious effects of astrocytic NF-κB activation include an increased excitotoxicity in 
postnatal rats (Acarin et al., 2001) and an impaired neurite outgrowth demonstrated in 
cultured rat astrocytes (de Freitas et al., 2002). Further studies showed that inhibition of 
astroglial NF-κB activation improved functional recovery after mouse spinal cord injury 
(Brambilla et al., 2005) and EAE (Brambilla et al., 2009). Collectively, these findings indicate a 
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potential role for the astrocytic NF-κB pathway for the therapeutic treatment of CNS 
diseases.  
 
4.1.7 No impact of LAQ on remyelination after cuprizone withdrawal 
Therapeutic treatment with 25 mg/kg LAQ during the remyelination phase after six 
weeks of cuprizone challenge displayed similar extensive remyelination in LAQ- and vehicle-
treated mice. Extensive remyelination was already detected four days after cuprizone 
withdrawal. The myelin content appeared similar in the corpus callosum of both treatment 
groups. This was further strengthened by the similar numbers of mature oligodendrocytes in 
LAQ- and vehicle-treated animals.  
These results are further supported by recently published findings that LAQ did not 
directly affect primary mouse oligodendroglial cells (Brück et al., 2012). In this study LAQ did 
not exert effects on oligodendroglial viability and staurosporin-induced cell death in vitro 
(Brück et al., 2012). Taken together, these data indicate that LAQ does not show any marked 
effects on oligodendroglial cells or remyelination.  
 
4.1.8 No effect of LAQ on LPC-induced demyelination  
In contrast to the findings in the cuprizone model, LAQ demonstrated no significant 
effect on LPC-induced demyelination, a model with focal rapid demyelination. The amount 
of LPC-induced demyelination was similar in vehicle-treated mice and in animals treated 
with 25 mg/kg LAQ. Even higher doses of LAQ (40 mg/kg) did not show any effect on the 
amount of LPC-induced demyelination compared to vehicle-treated mice. 
This lacking effect on LPC-induced demyelination might be due to differences in the 
underlying pathological mechanism of the two different models of toxic (focal versus global) 
cerebral demyelination. Potential reasons for the lack of effect of LAQ on LPC-induced 
demyelination could be the different targets of the toxins: LPC is directly toxic for myelin and 
glial cells whereas the toxic effects of cuprizone appear to be mediated by astrocytes 
(Woodruff and Franklin, 1999b; Raasch et al., 2011). A second possible explanation for the 
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observed difference could be the time course of demyelination in both models: LPC-induced 
demyelination is very quick, it can be observed already four days after injection, whereas the 
cuprizone-induced demyelination takes place over several weeks (over five to six weeks) 
(Ludwin, 1978; Hiremath et al., 1998). A third factor could be the tissue damage: LPC-
induced demyelination is slightly destructive and leads at least partially to BBB damage. 
Hence, infiltration of peripheral inflammatory cells cannot be excluded. Finally, the lacking 
effect of LAQ on LPC-induced demyelination might also be related to the fact that astrocytic 
NF-κB activation does not play a crucial role in LPC-mediated demyelination. This is further 
supported by the finding that mice lacking constitutive astrocyte-specific NF-κB activation 
also showed similar LPC-induced demyelination as wild type mice (Raasch et al., 2011). 
 
4.1.9 Pronounced effects of LAQ on cuprizone-induced pathology compared 
to other immunomodulatory drugs 
In the present study, nearly complete preservation of myelin and axons were 
observed under preventive therapy with LAQ in the cuprizone model. So far, LAQ is the only 
substance with marked effects in the murine cuprizone model. Only fingolimod, a 
sphingosine 1-phosphatate receptor agonist, attenuated cuprizone-induced demyelination, 
whereby moderate callosal demyelination was still observed in fingolimod-treated mice 
compared to marked demyelination in controls (Kim et al., 2011). Treatment with fumaric 
acids (trans-butenedioic acids) did not affect demyelination or glial reactions in this model 
(Moharregh-Khiabani et al., 2010). The present thesis showed that LAQ did not affect 
remyelination after cuprizone withdrawal. Similar negative effects on remyelination were 
reported for fingolimod in this model (Kim et al., 2011). Corticosteroids impaired 
remyelination after cuprizone-induced demyelination (Clarner et al., 2011). However, statins 
showed inhibitory effects on remyelination after cuprizone challenge (Miron et al., 2009).  
Up to now, there are no reports on the effects of glatiramer acetate on cuprizone-induced 
pathology. However, glatiramer acetate was shown to enhance oligodendrogenesis and 
remyelination after LPC-induced demyelination in mice (Skihar et al., 2009). Furthermore,   
in vitro studies demonstrated that supernatants from human glatiramer acetate-reactive T 
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lymphocytes potentiated oligodendrocyte numbers in rodent and human OPC cultures 
(Zhang et al., 2010). 
 
4.1.10 Further potential factors contributing to central LAQ effects  
Previous studies reported that LAQ exerted neuroprotective effects by modulation of 
BDNF. Studies in the EAE model revealed a more severe EAE course in mice constitutively 
lacking BDNF and treated with LAQ compared to wild type animals (Thöne et al., 2012). 
Furthermore, studies in MS patients demonstrated that LAQ-treated MS patients showed 
higher serum levels of BDNF (Thöne et al., 2012).  
BDNF is expressed by multiple cell types including neurons and glia in the adult CNS 
(Riley et al., 2004). Especially astroglial BDNF seems to play a role in neuroprotection since 
astroglial BDNF was up-regulated after treatment with several neuroprotective compounds 
in cultured mouse and rat astrocytes (Labie et al., 1999; Mizuta et al., 2001; Ohta et al., 
2002; Cardile et al., 2003). Further studies reported an up-regulation of BDNF in primary rat 
astrocytes by NF-κB after stimulation with TNFα (Saha et al., 2006). Additionally, BDNF also 
activated NF-κB in cultured rat hippocampal neurons (Kairisalo et al., 2009) further 
supporting the view that LAQ might exert its beneficial effects via modulating astrocytic    
NF-κB activity.  
BDNF seems also play a role in the cuprizone model since BDNF protein levels were 
reduced in the corpus callosum of mice after cuprizone treatment (VonDran et al., 2011). 
Furthermore, mice with constitutively reduced levels of BDNF exhibited increased numbers 
of oligodendrocyte progenitors and reduced levels of myelin proteins during de- and 
remyelination processes after cuprizone (VonDran et al., 2011).  
Phase III studies indicate that LAQ treatment leads to reduced brain atrophy and 
disability (Comi et al., 2012). The present experimental data and these clinical findings 
suggest that the effects of LAQ are not limited to inflammatory focal lesions in MS. 
 
 




In conclusion, preventive LAQ treatment led to reduced cuprizone-induced 
demyelination, microglial activation, axonal damage, astrogliosis and apoptosis. 
Furthermore, LAQ treatment decreased astrocytic NF-κB activation despite similar cuprizone 
concentrations in the brains of LAQ- and vehicle-treated mice. These effects were 
independent of T and B cells. However, LAQ did not affect remyelination after cuprizone 
withdrawal or LPC-induced focal demyelination. Taken together, these data together with 
the clinical findings suggest a CNS-protective effect of LAQ by modulation of the astrocytic 
inflammatory response via NF-κB down-modulation. These findings indicate that LAQ might 
be a promising future treatment of MS and potentially also other neurological diseases. 
 
4.2 Less cuprizone-induced demyelination and astrocytic NF-κB 
activation in transgenic mice overexpressing human GFAP  
4.2.1 Regular cerebral myelin and oligodendrocyte density in naïve 
Tg(hGFAP) transgenic mice 
Naïve mice overexpressing human GFAP showed regular cerebral myelin content and 
regular densities of mature oligodendrocytes at the age of eight weeks compared to their 
wild type littermates. Density of activated microglia was also similar in transgenic and wild 
type animals. Compared to wild type mice, animals overexpressing human GFAP showed 
increased astrogliosis and reactive astrocytes at the age of eight weeks.  
The finding of regular myelin in these mice is in accordance with previous studies 
demonstrating regular myelin content in 13-day-old Tg(hGFAP) animals by electron 
microscopy (Messing et al., 1998). Previous studies reported an increase of activated 
microglia at four month of age in these naïve transgenic mice which was assessed by 
quantitative PCR of brain samples (Hagemann et al., 2005). This increased microglial 
activation appeared to be due to an initiated stress response of astrocytes leading to an 
activation of microglia (Hagemann et al., 2005). In the present work, density of activated 
microglia did not seem to be increased in naïve animals, but microglial density was only 
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assessed histologically. The data on age-related increased astrogliosis in these transgenic 
mice are in line with previous publications (Messing et al., 1998). Another transgenic mouse 
line (Tg 73.4) overexpressing similar hGFAP levels as the Tg(hGFAP) mice used in this thesis 
(line Tg 73.7) displayed also GFAP levels that were three- to five-fold higher than in wild type 
animals at the age of 14 days. This elevation even increased to over 10-fold in in Tg 73.4 
mice that were aged one year or older (Messing et al., 1998).  
 
4.2.2 Reduced oligodendroglial apoptosis in Tg(hGFAP) mice 
After one week of cuprizone, both wild type and transgenic mice displayed reduced 
body weights in relation to their original weights. However, significantly higher relative 
weight gain was observed in Tg(hGFAP) animals after four, five and six weeks of cuprizone 
challenge. After one week of cuprizone, oligodendroglial apoptosis was reduced by 80% in 
Tg(hGFAP) mice compared to their wild type littermates. Mature oligodendrocytes were 
reduced by 28% in wild type animals whereas transgenic mice still showed similar densities 
of detectable oligodendrocytes comparable to oligodendroglial levels in naïve transgenic and 
wild type animals. These data suggest that astrocytic dysfunction in these transgenic mice 
led to reduced astrocyte-mediated oligodendroglial cell death compared to wild type 
animals. 
 
4.2.3 Less cuprizone-induced demyelination in Tg(hGFAP) mice 
After six weeks of cuprizone, the callosal myelin appeared present in animals 
overexpressing human GFAP compared to almost complete demyelination in wild type 
littermates as shown by histological examination. These findings indicate that the astrocytic 
changes related to the overexpression of human GFAP are responsible for the seemingly still 
present myelin in Tg(hGFAP) mice after cuprizone challenge. Future examinations are under 
way to determine which astrocytic factors and upstream pathways are responsible for the 
differential effects of cuprizone in Tg(hGFAP) animals compared to wild type animals. 
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4.2.4 Reduction of cuprizone-induced microglial activation and axonal 
damage in Tg(hGFAP) mice 
After six weeks of cuprizone, acute axonal damage was almost absent in transgenic 
mice. The density of axonal spheroids was 97% higher in wild type animals compared to 
Tg(hGFAP) mice. At this time point, the density of activated microglia within the corpus 
callosum was 75% higher in the wild type group compared to the transgenic group. 
Differences in cerebral astrogliosis were already obvious in naïve transgenic mice at eight 
weeks of age. Hence, it was not possible to quantify and compare fiber gliosis between 
transgenic and wild type animals after six weeks of cuprizone challenge since the level of 
astrogliosis was already different in naïve mice. 
 
4.2.5 Similar cerebral cuprizone concentrations in Tg(hGFAP) and wild type 
mice 
Mass spectrometry analyses revealed no significant differences between cerebral 
cuprizone concentrations of wild type and Tg(hGFAP) mice after one and six weeks of 
cuprizone. However, absolute values of cuprizone concentrations in the brain were higher in 
transgenic compared to wild type animals. These data indicate that the reduced cuprizone-
induced changes in Tg(hGFAP) mice cannot be related to lower cerebral cuprizone 
concentrations in these animals. 
The findings mentioned above argue against a peripheral effect caused by GFAP-
expressing cells outside the CNS. However, these peripheral cells exist. Previous studies 
showed that enteric glial cells were also rich in GFAP (Jessen and Mirsky, 1980). These cells 
extend throughout the different neural plexus, surround neuronal cell bodies and axons and 
contact blood vessels and epithelial cells. Further GFAP-expressing cells outside the CNS 
include satellite cells that envelope neurons, non-myelinating Schwann cells that surround 
non-myelinating axons as well as mesenchymal stellate cells in organs including liver, kidney, 
pancreas, lungs and testes. Although the functional role of these astrocytes-related cells are 
widely unknown, they appear to share astrocytic functions in tissue repair and scar 
formation as well as regulation of local immune and inflammatory responses (Sofroniew and 
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Vinters, 2010). However, the present data with similar cerebral cuprizone concentrations in 
both groups argue against an interference of GFAP-expressing cells outside the CNS.  
 
4.2.6 Reduction of astrocytic NF-κB activation in Tg(hGFAP) mice 
After six weeks of cuprizone, transgenic mice overexpressing human GFAP showed a 
reduced astrocytic NF-κB activation in vivo. The number of astrocytes with nuclear 
translocation of p65 was reduced by 80% in transgenic compared to wild type animals. These 
results were further strengthened by unpublished in vitro data showing a reduction of NF-κB 
activation by approximately 56% in transgenic mice as evidenced by NF-κB reporter assays 
(oral communication by Dr. N. Kramann, Dept. of Neuropathology, University Medical Center 
Göttingen, Germany). The observed findings of reduced astrocytic NF-κB activation in 
Tg(hGFAP) animals suggest that the NF-κB pathway is affected in these transgenic mice. 
Together with data of LAQ experiments these results indicate that astrocytic NF-κB 
activation plays a crucial role for cuprizone-induced pathology.  
Further evidence for an involvement of astrocytic NF-κB pathway in human GFAP 
transgenic animals comes from previous publications. In three-weeks-old Tg(hGFAP) mice, 
numerous stress response genes showed increased transcript levels. The nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) expression was up-regulated and also the genes regulated 
by Nrf2 through the antioxidant response element (ARE) were activated (Hagemann et al., 
2005). Lacking Nrf2 in constitutive Nrf2-deficient mice seemed to accelerate NF-κB-mediated 
pro-inflammatory reaction (Li W. et al., 2008). This result was further strengthened by the 
observation that diverse Nrf2 activators attenuated LPS-induced NF-κB activation in human 
cancer cells (Jeong et al., 2004). Previous studies in human hepatoma cells showed that     
NF-κB directly suppressed Nrf2 signaling at the transcription level since NF-κB/p65 competed 
against Nrf2 for the transcription co-activator cyclic adenosine monophosphate (cAMP) 
response element-binding protein (CREB) (Liu et al., 2008). Further studies are needed to 
shed light on the interplay between Nrf2 and NF-κB. 
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4.2.7 Evidence for altered astrocytic function in Tg(hGFAP) mice 
Recent publications suggest an altered astrocytic function in Tg(hGFAP) mice. In vitro, 
astrocytes from these animals showed a disrupted cytoskeletal network and suppressed 
astrocytic growth (Cho and Messing, 2009). Furthermore, the authors demonstrated 
decreased astrocytic proliferation, increased astrocytic cell death and higher vulnerability to 
H2O2 compared to cells from wild type mice. These findings provide evidence for 
dysfunctional astrocytes in these transgenic animals.  
Factors contributing to astrocytic dysfunction in these transgenic mice might be 
related to differences in the GFAP amino acid sequence between man and mice.                 
The positions of the two mutation hotspots in AxD are Arg79 and Arg239. The position of 
Arg79 is equivalent in human and mouse, but the position of amino acid 239 differs in both 
species (Brenner et al., 1990), since the mouse sequence is offset from the human sequence 
by the absence of three residues in the head domain. However, further studies are necessary 
to clarify which factors contribute to astrocytic dysfunction in Tg(hGFAP) mice. 
 
4.2.8 Conclusion 
In conclusion, transgenic mice overexpressing human GFAP showed reduced 
cuprizone-induced demyelination, microglial activation and acute axonal damage after six 
weeks of cuprizone. These transgenic mice demonstrated reduced oligodendroglial 
apoptosis and loss after short cuprizone challenge. Furthermore, transgenic mice showed 
decreased astrocytic NF-κB activation in vivo and in vitro. Taken together, these findings and 
the data from recent publications provide evidence for dysfunctional astrocytes with 
reduced NF-κB activation, and recently reported increased Nrf2 expression in these 
transgenic mice. The reduced astrocytic NF-κB activation might partly explain the reduced 
cuprizone-induced changes observed in these transgenic mice. 
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4.3 No marked direct effects of short-term cuprizone challenge on 
astrocytic survival in vitro and on glial cells in vivo 
4.3.1 No effect of cuprizone on astrocytic survival, but on astrocytic 
migration in vitro 
In the present study, treatment with 1 µM up to 100 µM cuprizone showed no effects 
on mitochondrial respiration and cell damage in primary astrocytes. However, high 
cuprizone concentrations (10 µM and 100 µM) seemed to mildly inhibit astrocytic migration 
in vitro. These high cuprizone concentrations, especially the highest concentration of         
100 µM cuprizone, are far above the relevant intracerebral cuprizone concentrations in vivo. 
This is supported by the in vivo mass spectrometry data of the present thesis which revealed 
concentrations of < 1 µM cuprizone per gram brain tissue. Mice treated with cuprizone for 
one or six weeks showed cerebral cuprizone concentrations ranging between ≤ 180 nM and 
≤ 510 nM cuprizone per gram brain tissue. The highest concentration of 100 µM cuprizone 
used in these assays is in line with other in vitro studies in rat oligodendrocytes using 100 µM 
cuprizone or even higher concentrations (Pasquini et al., 2007). Importantly, only astrocytic 
survival and migration were evaluated in the present study. More detailed cuprizone effects 
such as the astrocytic secretion of cytokines or chemokines which may potentially influence 
oligodendrocyte survival have not been investigated. Further examinations are necessary to 
clarify cuprizone-induced indirect effects mediated by astrocytes on oligodendrocytes. 
However, previous studies did not find clear evidence for cuprizone-induced 
astrocyte-mediated effects on oligodendrocytes. Treatment of primary oligodendrocyte 
cultures with conditioned medium from cuprizone-treated astrocytes did not lead to 
changes in oligodendroglial cell viability (Pasquini et al., 2007). Additionally, cuprizone did 
not affect astrocytic NF-κB activation in vitro which was assessed by NF-κB reporter assays 
(oral communication by Dr. N. Kramann, Dept. of Neuropathology, University Medical Center 
Göttingen, Germany). Taken together, these data indicate no conclusive effect of cuprizone 
in vitro. Potential explanations for the observed differences in vivo and in vitro could be the 
different time courses: In vivo, early effects of cuprizone were observed one or six weeks 
after cuprizone challenge whereas in vitro, astrocytes were treated only for 24 h with 
cuprizone. However, oligodendrocyte death in vivo already starts early after initiation of 
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cuprizone challenge and apoptotic cells are already seen after two days of cuprizone diet in 
the corpus callosum and cortex (Buschmann et al., 2012) indicating that potential direct       
in vitro effects of cuprizone on glial cells might already be detectable after short incubation 
times.  
A second explanation could be that metabolic processes in vivo are necessary for 
cuprizone-induced pathology involving potential metabolite(s). To control for potential 
metabolites, primary astrocytes were also treated with serum from cuprizone-treated mice 
in this thesis, but there were no effects on astrocytic mitochondrial respiration and 
migration capacity either. Plasma levels of cuprizone itself are low as evidenced by the 
spectrometric data provided in this thesis. However, the levels and existence of potential 
cuprizone metabolites are not known. The effect of serum on astrocytic cell damage was not 
evaluated since the presence of serum interfered with the corresponding assay. To date, 
there is no evidence for a metabolic transformation of cuprizone (Kipp et al., 2009).  
 
4.3.2 Presence of oligodendrocytes and astrocytes after focal intracerebral 
injection of cuprizone 
Intracerebral injections of different agents - such as cuprizone or serum from 
cuprizone-treated mice - did not affect local astrocytes, oligodendrocytes or myelin content.  
Potential reasons for the lack of effect of cuprizone after focal injection could be the 
short time course or low exposure to the corresponding agents: After focal injection of 
cuprizone, mice were already sacrificed after four days. Alternatively a single injection might 
not have been sufficient for direct effects on glial cells. Potential confounds caused by 
peripheral effects such as a locally damaged BBB after focal injection could also contribute to 








In conclusion, in vitro treatment with cuprizone or serum from cuprizone-treated 
mice did not affect mitochondrial respiration and astrocytic cell damage, but high cuprizone 
concentrations mildly inhibited the migration capacity in primary astrocytes. Focal 
intracerebral injection of these agents did not affect myelin content or detectable astro- and 
oligodendroglial cells. Taken together, published data and data from the present work 
indicate no clear in vitro effect of cuprizone on astrocytes. In addition, the previously 
published in vitro effects of cuprizone on oligodendroglial cells also remain inconclusive. This 
in vivo part of this thesis indicates no direct effect of cuprizone or serum from cuprizone-
treated mice on myelin content and detectable astro- and oligodendroglial cells after 
intracerebral injection. These results indicate that the mechanism of action of cuprizone 
differs in vivo from in vitro and is not well understood. Further studies are required to clarify 
its mechanism of action. 
 
4.4 Concluding remarks on astrocytic involvement in 
demyelinating diseases 
The current findings emphasize the important contribution of astrocytes during toxic 
demyelination. However, astrocytes also play a crucial role in human demyelinating diseases 
as clearly indicated by the finding of autoantibodies against AQP4 in the MS-related disease 
NMO (Lennon et al., 2005).  
Astrocytes contribute to pathological processes including the production of 
neurotrophic factors, the expression of ion channels and neurotransmitters, as well as the 
secretion of chemokines and cytokines (Sofroniew, 2009). Astrocytes have a dual role for 
demyelinating diseases such as MS and can mediate both deleterious and beneficial effects. 
On the one hand astrocytes can prevent widespread tissue damage by formation of a glial 
scar around demyelinated lesions. Further beneficial effects of reactive astrocytes include 
the mediation of anti-inflammatory responses, suppression of T cell activation and repair of 
the BBB (Nair et al., 2008). On the other hand reactive astrocytes produce hyaluron which 
accumulates in chronic demyelinated MS lesions and inhibits OPC maturation (Back et al., 
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2005). Deleterious effects also include the production of proinflammatory cytokines driving 
inflammation, BBB leakage, and invasion of immune cells into lesions (Nair et al., 2008).  
Up to now, the role of astrocytes for MS is not fully understood, but some studies 
strengthen that astrocytes might be important for MS. The voltage-sensitive sodium channel 
Nav1.5 is up-regulated in astrocytes in active and chronic MS lesions (Black et al., 2010). 
GFAP is increased in CSF in patients with progressive MS (Malmeström et al., 2003). 
Furthermore, serum levels of antibodies to the astrocytic inwardly rectifying potassium 
channel (KIR) 4.1 are elevated in MS patients compared to healthy persons or those with 
other neurological diseases (Srivastava et al., 2012). 
The data of the present thesis suggest that reduction of the NF-κB activation in 
astrocytes might be a potential future therapy for demyelinating diseases such as MS.       
The effects of LAQ on astrocytic activation are CNS-intrinsic and might explain that LAQ has 
more pronounced effects on sustained disability progression and brain atrophy than on 
relapses. The findings from the present work emphasize the role of modulation of astrocytic 
activation as promising therapeutic target for patients with demyelinating diseases such as 
MS.  
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Astrocytes play a crucial role in demyelinating diseases which has been highlighted by 
pathogenetic autoantibodies against the astrocytic water channel aquaporin-4 in the MS-
related disease neuromyelitis optica. Cuprizone-induced demyelination takes place with an 
intact BBB whereby activation of nuclear factor kappa of activated B cells (NF-κB) plays a key 
role for cuprizone-induced pathology. Recent clinical studies in MS suggest that laquinimod 
(LAQ) might have direct CNS-protective effects in addition to its known peripheral anti-
inflammatory properties. The present thesis evaluated intrinsic and therapy-induced 
astrocytic effects on toxic demyelination in mice.  
The first part of this thesis evaluated the impact of LAQ on toxin-induced changes     
in vivo. After one week of cuprizone the density of oligodendrocyte apoptosis was 
significantly reduced in mice treated with 25 mg/kg LAQ compared to vehicle-treated 
animals. After six weeks of cuprizone the following findings were observed: Demyelination 
was decreased in a dose-dependent manner in mice treated with 0, 5 and 25 mg/kg LAQ. 
Microglial activation, axonal damage and reactive astrogliosis were also reduced under       
25 mg/kg LAQ compared to the vehicle group. Astrocytic NF-κB activation assessed by 
nuclear translocation of p65 in GFAP-positive astrocytes was significantly decreased by 46% 
after LAQ treatment. Similar findings were demonstrated in recombination activating gene 
1-deficient mice treated with 25 mg/kg LAQ indicating that LAQ exerted effects on 
cuprizone-induced pathology independent of T and B cells. Mass spectrometry revealed 
similar cerebral cuprizone concentrations in wild type mice treated with and without LAQ 
after one and six weeks of cuprizone. Therefore, the observed differences in cuprizone-
induced pathology cannot be explained by different cuprizone concentrations. However, 
LAQ showed no impact on remyelination after previous cuprizone challenge or on 
lysolecithin-induced demyelination. These findings indicate that LAQ might protect from 
cuprizone-induced pathology through CNS-intrinsic mechanisms by reducing the astrocytic 
NF-κB activation. Recently published in vitro data support these findings by demonstrating 
that LAQ directly inhibited the astrocytic, but not microglial, NF-κB activation and thereby 
down-regulated the astrocytic pro-inflammatory response. 
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The second part of this work investigated the impact of increased astrocytic GFAP 
expression on cuprizone-induced pathology in vivo. Naïve transgenic mice overexpressing 
human wild type GFAP referred to as Tg(hGFAP) displayed increased astrogliosis, but regular 
myelin content as well as oligo- and microglial densities, compared to wild type animals. 
After one week of cuprizone, transgenic mice revealed reduced oligodendroglial apoptosis 
and increased densities of mature oligodendrocytes compared to wild type animals. After six 
weeks of cuprizone less demyelination, microglial activation and axonal damage was 
observed in Tg(hGFAP) compared to wild type mice. Astrocytic NF-κB activation evidenced 
by nuclear translocation of p65 was reduced by 80% in Tg(hGFAP) compared to wild type 
mice. Spectrometric cuprizone concentrations in the brain were similar in both groups after 
one and six weeks of cuprizone. Therefore, the observed changes in cuprizone-induced 
pathology cannot be explained by different cuprizone concentrations. The reduced 
cuprizone-related pathology in Tg(hGFAP) is likely to be related to at least two factors:        
(1) reduced astrocytic NF-κB activation as well as (2) widespread astrocytic dysfunction such 
as compromised proliferation, reduced proteosomal activity and decreased resistance to 
stress demonstrated previously in vitro in these transgenic mice. 
The third part of the thesis assessed direct effects of cuprizone on astrocytes in vitro 
and in vivo. In vitro, neither cuprizone nor serum from cuprizone-treated mice affected 
mitochondrial respiration and astrocytic cell damage, but high cuprizone concentrations 
mildly inhibited the migration capacity in primary mouse astrocytes. In vivo, focal 
stereotactic intracerebral injection of cuprizone or serum from cuprizone-treated mice did 
not affect the myelin content or the presence of astrocytes and oligodendrocytes. However, 
this thesis did not assess more detailed cuprizone effects such as astrocytic cytokines which 
may potentially influence oligodendrocyte survival in vitro. The current results suggest that 
the mechanism of action of cuprizone differs in vivo from in vitro and is still not well 
understood. 
The findings from the present work and recently published data demonstrate that 
cuprizone-induced pathology is mediated by astrocytic NF-κB activation. These data 
emphasize the potential role of modulating astrocytic activation for future treatment of 
demyelinating diseases such as MS. 
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